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BCL6A is a transcriptional repressor that acts on a diverse variety of genes, including 
those encoding proteins responsible for maintaining DNA integrity, acting as cell cycle 
checkpoints and mediating apoptosis, and in different cell types but especially immune cells. 
BCL6A facilitates B cell survival necessary for germinal centre formation and development of 
high-affinity antibodies, and is also essential for promoting CD4+ T cell differentiation into 
Tfh cells while inhibiting the generation of other T cell lineages, such as Th1, Th2 and Th17. 
It is also crucial in the differentiation of dendritic cells and macrophages and has additional 
non-haematopoietic roles. BCL6A is a proto-oncogene, which is highly expressed in many non-
Hodgkin’s lymphomas, such as diffuse large B cell lymphoma and follicular lymphoma. 
BCL6A expression is negatively regulated by STAT5 through tetrameric binding sites in its 
promoter region. In many cases, the disruption of these regulatory sites is responsible for the 
up-regulation of BCL6A expression underlying oncogenesis. 
Zebrafish represent a relevant and convenient model to study immune cells and their 
perturbation due to the high conservation of haematopoiesis and the genes regulating this 
process between zebrafish and mammals. To further expand our knowledge of BCL6A 
function, this thesis aimed to: (i) characterise the zebrafish bcl6a gene and its regulation by 
STAT5, (ii) investigate the impact of bcl6a ablation on growth and survival and (iii) 
characterise the role of bcl6a in immune cell development and function. 
Bioinformatics analysis of zebrafish gene databases with human BCL6A and BCL6B 
sequences identified putative homologues for each gene, called bcl6a and bcl6b, respectively, 
as well as an additional fish-specific duplicate, bcl6ab. Alignment of the human and zebrafish 




domains. In addition, the promoter of bcl6a possessed nearly identical tetrameric STAT5 
binding sites to those found in human BCL6A gene promoter. Whole-mount in situ 
hybridization (WISH) revealed early embryonic expression of bcl6a in the lateral mesoderm, 
with later expression seen in the brain, eye and thymus. Zebrafish STAT5 proteins, especially 
Stat5.2, were shown to be involved in the negative regulation of bcl6a. 
CRISPR/Cas9 genome editing was utilised to target exon 3 of the zebrafish bcl6a gene 
encoding the BTB/POZ domain. This created a non-functional allele, named mdu21, with a 
combined 28 bp deletion and 59 bp insertion that introduced a premature stop codon, which 
resulted in a severely truncated encoded protein. Analysis of the progeny from heterozygote 
mutant (bcl6awt/mdu21) in-crossing revealed significant retardation in development and growth 
of bcl6amdu21/mdu21 embryos from 14 days post fertilisation (dpf) compared to wild-type 
embryos. Additionally, their relative survival declined from 14 dpf with none surviving to 60 
dpf. The bcl6awt/mdu21 fish showed an intermediate phenotype. 
Immune cell development was investigated using WISH with immune cell markers on 
individually genotyped embryos. This revealed significant decreases in ikaros, a marker of T 
cell progenitors, and rag1, a marker of mature T cells in the bcl6amdu21/mdu21 embryos. 
Moreover, the number of cells expressing l-plastin, a marker of leukocytes including 
macrophages, was significantly reduced in both bcl6awt/mdu21 and bcl6amdu21/mdu21 embryos, 
while no significant difference was observed in the number of cells expressing mpo, a marker 
of granulocytes. When infected intravenously with green fluorescent protein (GFP) expression 
E.coli at 4 dpf, increased bacterial numbers and reduced survival were observed in 
bcl6amdu21/mdu21 embryos from 12 hour post injection. To further investigate the macrophage 
population the bcl6a mutant allele was transferred onto a mpeg:GFP+ background, whereby 




at 4 dpf identified a significant decrease in the total number and motility rate of the GFP+ 
macrophages at the wound site in bcl6amdu21/mdu21 embryos. Collectively, this suggests 
dysfunctional macrophages following bcl6a ablation. 
The work described in this thesis has expanded our knowledge about the evolution and 
function of bcl6a in zebrafish. It has revealed an essential role in maintaining a normal growth 
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Danio rerio 







 Introduction  
Chapter 1 
  2 
1.1 Haematopoiesis 
Haematopoiesis describes the process by which blood and immune cells are 
formed. In mammals, haematopoiesis occurs in distinct waves at discrete anatomical 
sites. The so-called primitive wave is initiated in the embryonic mesoderm, where a 
specific group of precursor cells differentiates into primitive erythroid and myeloid 
cells at distinct sites, with these precursors lacking the capacity for self-renewal or 
pluripotency (McGrath & Palis 2005; Medvinsky, Rybtsov & Taoudi 2011; Tober et 
al. 2007). Later a group of erythroid-myeloid progenitors (EMPs) arise that are able to 
generate both erythroid and myeloid cells. The definitive wave commences with the 
generation of haematopoietic stem cells (HSCs) in the aorta/gonad/ mesonephros 
(AGM) region. (Ivanovs et al. 2017; Medvinsky, Rybtsov & Taoudi 2011). The HSCs 
migrate to the fetal liver and spleen, and before birth the HSCs migrate to colonise the 
bone marrow and lymphocyte precursors to colonise the thymus, where they remain for 
the rest of adult life (Baron, Isern & Fraser 2012; Cullen et al. 2014). 
HSCs are capable of giving rise to all circulating blood cells lineages (Figure 
1.1). In the ‘classical’ version of definitive haematopoiesis, HSCs undergo asymmetric 
division to generate multipotent progenitors (MPPs) as well as refresh the HSC 
population. MPPs further differentiate into either common myeloid progenitors (CMPs) 
or common lymphoid progenitors (CLPs). The CMPs, in turn, differentiate into two cell 
types, granulocyte-monocyte progenitors (GMPs) or megakaryocyte-erythroid 
progenitors (MEPs). GMPs later give rise to granulocytes and monocytes from which 
macrophages differentiate in tissues, while MEPs gives rise to megakaryocytes from 
which platelets are formed and red blood cells (RBCs) (Notta et al. 2016; Rieger & 
Schroeder 2012). CLPs, on the other hand, differentiate into either B cell progenitors, 
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from which mature B cells are derived, or T and NK cell progenitors, which yield the 
various T and NK cell populations (Allman, Aster & Pear 2002; Lin, Yoder & 
Yoshimoto 2014). Immature B cells reside in the bone marrow, and then develop into 
transient B cells, which migrate to the peripheral blood. After B cell maturation, they 
return to the bone marrow, where the mature B cells start localisation in the spleen and 
lymph nodes (Jacobsen & Osmond 1990). T cells mature and differentiate in the thymus 
through positive and negative selection (Ashton-Rickardt et al. 1994), then differentiate 
into T cell subsets including effector, helper, memory, cytotoxic, regulatory and natural 
killer T cells (Gutcher & Becher 2007; Sallusto et al. 1999; Singh et al. 2013).  
1.2 Control of haematopoiesis 
Haematopoiesis is an essential process for maintaining the health of an 
organism, and is regulated by several layers of control. These can be divided into ‘cell-
intrinsic’ factors (transcriptional factors, genetic modifications, metabolism, etc.) and 
‘cell-extrinsic’ factors (cytokines, chemokines, oxygen levels, etc.) (Cabezas-
Wallscheid et al. 2014; Ciau-Uitz et al. 2014; Metcalf 1998; Olsson et al. 2016; Rieger 
et al. 2009). Collectively these factors maintain tight control of haematopoiesis, with 
their dysregulation often leading to perturbed haematopoiesis and diseases. 
1.2.1 Transcription factors 
Transcription factors are proteins that regulate gene expression, typically 
through binding to specific DNA elements in the regulatory region of key target genes. 
They can serve as activators or repressors of transcription, depending on the various 
co-activators and co-repressors that they interact with (Lelli, Slattery & Mann 2012; 
Spitz & Furlong 2012). Haematopoiesis is regulated by a complex network of 
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transcription factors from a variety of different families, which represent the most 
important of the cell-intrinsic factors. These play essential roles in determining HSC 
quiescence/activation, progenitor lineage commitment as well as the proliferation, 
differentiation, survival and activation of haematopoietic cells (Kerenyi & Orkin 2010; 
Novershtern et al. 2011; Zandi, Bryder & Sigvardsson 2010). 
The transcription factors SCL and LMO2 play a central role in the primitive 
wave of  haematopoiesis (Barton, Gottgens & Green 1999; Bockamp et al. 2009; 
Hoang, Lambert & Martin 2016; Landry et al. 2009; Robb et al. 1996), with a key role 
for SCL in initiating blood cell formation in the early embryo (Scialdone et al. 2016) 
and LMO2 is important for the definitive wave of haematopoiesis (Durand & Dzierzak 
2005; Manaia et al. 2000; Medvinsky, Rybtsov & Taoudi 2011; Visvader et al. 1997; 
Yamada et al. 2000; Yamada et al. 1998). GATA2 and KLF1 represent key regulators 
for determining the fate of MPPs into either the myeloid or lymphoid lineage (Cheng 
et al. 2009; Moignard et al. 2013; Palis et al. 2010; Yu et al. 2009). c-MYB has been 
demonstrated to be a key regulator of HSC proliferation and lineage commitment 
choice (Bianchi et al. 2015; Greig, Carotta & Nutt 2008; Lu et al. 2008; Sandberg et al. 
2005), largely through its regulation of other haematopoietic transcriptional factors, 
including LMO2, KLF1, GATA2 and STAT5A (Bianchi et al. 2010; Lorenzo et al. 
2011). Disruption of c-MYB resulted in significantly decreased bone marrow HSCs, 
impaired haematopoiesis and a severe decrease in erythrocytes, megakaryocytes, 
neutrophils, monocytes and B-lymphocytes (Lieu & Reddy 2009; Sakamoto et al. 
2015). Similarly, RUNX1 regulates the expression of GATA2 and KLF1, as well as 
other transcription factors to influence myeloid cell development (Landry et al. 2008; 
Yokomizo et al. 2008). A number of lineage-specific transcription factors are also 
involved, with MEIS1 essential for platelet formation (Carramolino et al. 2010), 
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GATA1 for erythrocyte production (Moriguchi & Yamamoto 2014) and SPI1 (PU.1) 
for myeloid cell development (Genik et al. 2014). In terms of lymphocyte development, 
disruption in any members of the transcriptional complex containing EFB1, PAX5, 
IKAROS, RUNX1, FOXO1, SPI1 and E2A has significant impacts on differentiation 
along the B cell lineage from CLPs (Boller & Grosschedl 2014; Mandel & Grosschedl 
2010; Nechanitzky et al. 2013; Pongubala et al. 2008; Prasad et al. 2015; Ungerback et 
al. 2015; Zandi et al. 2012). Additional studies have shown that GATA3 and ThPOK 
are essential for the generation of early T cell precursors in the thymus (Banerjee et al. 
2013; Taghon, Yui & Rothenberg 2007; Wei et al. 2011), with TCF1 and LEF1 critical 
for specification of T cell fate from these progenitors (Steinke et al. 2014; Weber et al. 
2011; Yu & Xue 2013; Yu et al. 2012).  
1.2.2 Cytokine receptor signalling 
The principle mechanisms of cell-extrinsic control of haematopoiesis is through 
a network of cytokines and growth factors, which act via specific cell surface receptors 
expressed by target cells. Binding of a cytokine to its receptor triggers conformational 
changes that lead to activation of intracellular kinase, notably including the Janus kinase 
(JAK) family of tyrosine kinases. These phosphorylate the receptor and associated 
components to create docking sites for a raft of signalling molecules that are often 
phosphorylated as well. These include latent transcription factors called signal 
transducer and activator of transcription (STAT) proteins that become tyrosine 
phosphorylated, allowing homo- or hetero-dimerization and translocation to the 
nucleus. Here they can influence haematopoietic cell proliferation, differentiation, 
survival and activation by modulating the expression of key target genes (Dorritie, 
McCubrey & Johnson 2014; Greenfest-Allen et al. 2013; Morin-Poulard, Vincent & 
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Crozatier 2013). Signalling is under tight control, including by suppressor of cytokine 
signalling (SOCS) proteins that serve as a negative feedback loop (Croker, Kiu & 
Nicholson 2008). SOCS proteins regulate signalling through distinct mechanisms 
(Alexander & Hilton 2004), all involving binding via their SH2 domain to 
phosphorylated tyrosine residues on the cytokine or growth factor receptor complex 
(Inagaki-Ohara et al. 2013) to: (i) compete for binding sites with STATs (ii) to inhibit 
associated JAKs; (iii) to mediate degradation via their SOCS box recruitment of 
ubiquitin E3 ligase activity. 
1.3 Haematopoietic diseases 
1.3.1 Overview 
Haematopoiesis requires a wide network of transcription factors, cytokine 
receptors and other factors to function optimally. Mutation or dysregulation of many 
components of this network – including by external factors such as infection or injury 
– can lead to haematopoietic disease. These can be deficiencies – of a cell type or its 
function – or excesses, including malignancy. The type of disease is largely determined 
by which aspect of haematopoiesis is affected. Some blood disorders affect just red 
blood cells, including haemoglobinopathies, anaemias or polycythaemia vera, or white 
blood cells, including neutropenia and leucocytosis, or platelets, including 
thrombocytopenia and thrombocytosis, or lymphocytes, including immunodeficiency 
(Hoots & Shurin 2012; Weatherall & Clegg 2001). Other disorders effect multiple 
lineages, such as aplastic anaemia or severe combined immunodeficiency, due to an 
effect on an earlier progenitor cell (Buckley 2004; Cossu 2010; Szabo et al. 2000; 
Walne et al. 2012). 
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1.3.2 Lymphomas 
Lymphomas are a group of neoplasms that are derived from lymphocytes. With 
over 135000 new cases estimated in 2016 in the United States, lymphomas represent 
the fourth and sixth most common cause of cancer and death, respectively, in that 
country (Teras et al. 2016). Lymphomas are typically characterised by a number of 
symptoms, including painless enlargement of lymph nodes, night sweats, fever, 
itchiness, weight loss and general weakness. Lymphomas are divided into two major 
categories; Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) (Anderson, 
Armitage & Weisenburger 1998; Kuppers 2009a). 
Hodgkin lymphoma (HL) originates from immature B cells. These are usually 
localized to the peripheral lymph nodes, but malignant cells can also be found in other 
organs such as lung, liver and bone marrow. There are many subclasses of HL based 
on the histological characteristics and cancer cell type, including nodular sclerosis, 
lymphocyte-rich, mixed cellularity, lymphocyte-depleted and nodular lymphocyte-
predominant lymphoma (Kuppers 2009a; Landman-Parker & Gorde-Grosjean 2009). 
In HL, two types of tumour cells exist, including so called Hodgkin and Reed-Sternberg 
cells, and lymphocyte-predominant cells. Both cell types have mutated Ig heavy and 
light chain V gene rearrangements, which prove their B cell origins (Kuppers 2009b). 
They also retain expression of many germinal centre (GC) B cell markers, including 
BCL6 (Greiner et al. 2005; Schmitz et al. 2009). On the other hand, HRS cells express 
a diverse range of haematopoietic lineages markers, including CD3, GATA3 and 
NOTCH1 (T cell), CD20 and PAX5 (B cell), CSF1R (myeloid cell), ID2 (NK cell), 
CCL17 and FASCIN (dendritic cell) and CD15 (granulocyte) (Schmitz et al. 2009). 
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The non-Hodgkin lymphomas represent a diverse group of lymphoid tissue 
malignancies divided into specific categories of B cell and T cell lymphomas on the 
basis of histological characteristics, lymphocyte type and stage. The most common 
forms of NHL are diffuse large B cell lymphoma (DLBCL), which represent about 40% 
of the cases in North America and Europe, and follicular lymphoma (FL), with about 
30% of cases. Other common types of NHL are chronic lymphocytic leukaemia (CLL), 
peripheral T cell lymphoma, marginal zone B cell lymphoma and mantle cell 
lymphoma. The causes of NHL remain unclear, but there are many predisposing factors 
that play an important role in the onset of the disease, such as immunosuppression, 
infectious agents, such as HIV and H. pylori, as well as therapeutic agents and exposure 
to radiation, pesticide exposure and hair dyes. Race and familial factors, such as 
autoimmune diseases play a role (Anderson, Armitage & Weisenburger 1998; Chiu & 
Hou 2015; Lenz & Staudt 2010; Shankland, Armitage & Hancock 2012).  
B cell NHL is the most common lymphoid cancer (Teras et al. 2016). B cell 
NHL is typically characterised by chromosomal translocations, involving both 
oncogenes and tumour-suppressor genes, with persistent activation of B cells receptor 
signalling. Genetic analysis of DLBCL and FL (the most common forms of B-cell 
NHL) showed frequent chromosomal translocations in the oncogenes BCL2 or/and 
MYC (>40% of DLBCL and >85% of FL), which result in overexpression of these 
oncoproteins (Bohers et al. 2015; Iqbal et al. 2004; Lenz et al. 2008; Li et al. 2012; 
Pasqualucci et al. 2014). Previous studies revealed somatic mutations were most 
frequently identified in MLL2 (KMT2D) and MEF2B, encoding histone methyl 
transferase and calcium regulator genes, respectively (Cai, Chen & Armstrong 2015; 
Morin et al. 2011; Ortega-Molina et al. 2015; Ying et al. 2013; Zhang et al. 2015). Some 
cases of DLBCL showed double translocations, which usually have a bad prognosis 
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(Horn et al. 2013; Hu et al. 2013; Snuderl et al. 2010). Other frequent gene mutations 
in DLBCL include MYD88, CREBBP, TP53, PIM1, CARD11, EZH2 and BCL6A 
(Zhang et al. 2013). 
1.4 BCL6A 
1.4.1 The ZF-BTB/POK family 
The zinc finger broad complex/tram track/bric-a-brac (ZF-BTB) family, also 
known as the POK family, comprises a large number of proteins, which contain an N-
terminal BTB/POK domain and a C-terminal zinc finger domain, which was firstly 
identified in fruit-fly encoding essential proteins for its development (Zollman et al. 
1994). The BTB/POK domain is involved in mediating protein-protein interactions, 
especially complex formation with co-repressors, such as SMRT, NCoR, SIN3A or 
histone deacetylases (HDACs) (Brayer & Segal 2008; Chaharbakhshi & Jemc 2016; 
Chevrier & Corcoran 2014; Lee & Maeda 2012). The zinc finger domain largely 
mediates the sequence-specific binding of these transcription factors to target 
regulatory regions (Brayer & Segal 2008). The closely-related B cell lymphoma 6A 
(BCL6A) and BCL6B proteins are members of the ZF-BTB/POK family. 
1.4.2 BCL6A structure 
Human BCL6A consists of 706 amino acids, encoded by a gene comprising 10 
exons, with conserved STAT5 binding sites within the proximal promoter region 
(Figure 1.2). BCL6A comprises an N-terminal BTB/POZ domain, a central PEST 
domain and a C-terminal zinc finger domain comprising an array of six zinc fingers 
(Ahmad et al. 2003; Ghetu et al. 2008; Melnick et al. 2002). BCL6A forms complexes 
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via its BTB/POZ domain with corepressors, such as SMRT, NCOR, BCOR, MTA3 and 
CTBP1, to deliver its repressive action through recruitment of class I and II HDAC 
(Basso & Dalla-Favera 2010). The PEST domain contains a lysine motif that is a target 
of acetylation. Acetylation of this motif ablates the transcriptional repression of BCL6A 
(Bereshchenko, Gu & Dalla-Favera 2002). Additionally, the PEST domain mediates 
interactions with metastasis-associated protein 3 (Fujita et al. 2004). The zinc finger 
domain facilitates binding to specific DNA binding sites (Dent et al. 1997; Liu et al. 
2016), and is also responsible for protein-protein interaction (Miles et al. 2005), 
including recruitment of Class II histone deacetylases (HDACs) (Lemercier et al. 2002). 
1.4.3 BCL6A function 
The main function of BCL6A is to repress a set of genes that maintain DNA 
integrity, serve as cell cycle checkpoints or mediate apoptosis. These include ATR 
(ataxia telangiectasia and Rad3 related), CHEK1 (checkpoint kinase 1), TP53, PRDM1/ 
IRF4, PDCD2 and CDKN1A (cyclin-dependent kinase inhibitor 1A) (Baron et al. 2002; 
Parekh, Prive & Melnick 2008). Other genes suppressed by BCL6A include those 
involved in T cell-dependent antibody affinity maturation, such as CD69, CD44, 
CD23b, and NF-KB1 (Hatzi & Melnick 2014). 
BCL6A plays an essential role in B cells, including formation, survival, and the 
production of high-affinity antibodies (Basso & Dalla-Favera 2010). Bcl6a-deficient 
mice displayed a severe inflammatory reaction in multiple organs, such as the heart, 
lung and spleen, with distinctive eosinophilic infiltration (Yoshida et al. 1999). This 
indicates that BCL6A has a major regulatory role in the T helper 2 (Th2) cell mediated 
immunological responses. Mice expressing a mutant BCL6A unable to bind to co-
repressors also did not form B cell GCs (Huang, Hatzi & Melnick 2013; Niu 2002), 
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highlighting the key role for gene repression in mediating its function. Additionally, 
BCL6A has been shown to be involved in macrophage activity, with bone marrow 
derived macrophages in which Bcl6a was ablated showing disabled motility and 
disrupted morphology (Pixley et al. 2005; Toney et al. 2000). 
BCL6A ablation has also been shown to impact several parameters. Bcl6a 
knockout mice exhibit significantly decreased body weight postnatally compared to 
wild-type and heterozygote littermates (Dent et al. 1997; Yoshida et al. 1999), with 
Bcl6a knockout mice having severely reduced adipose mass (LaPensee et al. 2014). 
These mice also showed decreased survival, with Bcl6a knockout mice dying as early 
as 3 weeks of age, with most not surviving past 9 weeks. This appears to be the result 
of severe Th2-mediated inflammation of the heart, lungs, liver and spleen (Cattoretti et 
al. 2005; Dent et al. 1997). 
1.4.4 BCL6A in lymphoma 
BCL6A is considered oncogenic, being highly expressed in many lymphomas 
such as DLBCL and FL (Green et al. 2014; Wagner, Ahearne & Ko Ferrigno 2011). In 
several cases, this is mediated by translocations and other mutations of the BCL6A gene 
located on chromosome 3 at band q27. Most of the translocations occur within the 5' 
non-coding region involving fusion with the heavy and light immunoglobulin chain 
loci, which leads to deregulated expression. Additionally, translocations and deletions 
impacting on STAT5-binding sites in BCL6A promoter, which mediate repression of 
BCL6A, result in up-regulation of BCL6A expression that contribute in tumorigenesis 
(Walker, Nelson & Frank 2007). Such mutations have been reported in about 71% and 
100% of DLBCL and FL cases, respectively (Basso et al. 2010; Lenz & Staudt 2010; 
Polo et al. 2007). It has also been found that disruption of factors that participate in the 
Chapter 1 
  12 
negative regulation of BCL6A, such as IL-21R (interleukin 21 receptor), IRF8 
(interferon regulatory factor 8) and STAT5B (signal transducer and activator of 
transcription 5B), contribute to lymphomagenesis by indirectly enhancing BCL6A 
levels. The increased BCL6A expression leads to enhanced expression of oncogenic 
genes such as BCL2, MYC, CCND1 and BMI1 to facilitate lymphomagenesis (Hatzi & 
Melnick 2014).  
1.5 STAT5 
1.5.1 The STAT family 
The STAT protein family comprises seven members, STAT1, STAT2, STAT3, 
STAT5A, STAT5B and STAT6, which share a similar structure of six conserved 
protein domains (Steelman et al. 2004; Sternberg & Gilliland 2004). The N-terminal 
domain, also known as the oligomerization domain, plays an important role in the 
dimerization of STAT monomers and provides a platform for other protein-protein 
interactions (Benekli et al. 2003; Calo et al. 2003; Steelman et al. 2008; Sternberg & 
Gilliland 2004). It is also important in the deactivation of STATs through regulation of 
tyrosine dephosphorylation (Mertens & Darnell 2007). The coiled-coil domain 
mediates interactions with other proteins and has been implicated in receptor binding 
and nuclear translocation. The DNA-binding domain facilitates binding of STAT 
proteins to specific gene sequences, and plays a role in the nuclear export of 
phosphorylated STAT dimers (Benekli, Baumann & Wetzler 2009; Boucheron et al. 
1998; Zhang et al. 2003). The linker domain, between the DNA-binding domain with 
the SRC homology 2 domain, assists in DNA binding, transcription and 
nucleocytoplasmic shuttling (Marg et al. 2004; Yang et al. 1999). The SRC homology 
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2 domain is highly conserved and mediates interactions between STATs and specific 
phosphotyrosine residues on receptors, JAKs and other STAT monomers. Finally, the 
transcriptional activation domain in the C-terminal region is involved in positively 
regulating transcription. A conserved serine residue within this domain in some STATs 
provides an extra layer of phosphorylation-mediated regulation (Benekli, Baumann & 
Wetzler 2009; Calo et al. 2003; Levy & Darnell 2002). 
1.5.2 STAT5 protein function 
There are two highly similar STAT5 proteins in mammals, STAT5A and 
STAT5B, which are encoded by tandemly duplicated genes on chromosome 17. The 
main function of STAT5 is in transcriptional control. Following activation by cytokines 
and growth factors, STAT5 typically binds in the form of dimers or oligomers to 
clusters of canonical TTCNNNGAA binding sites within promoters of target genes. 
Stat5a knockout mice exhibited defective responses to prolactin, leading to 
undeveloped mammary glands (Creamer et al. 2010; Schmidt et al. 2014). On the other 
hand, Stat5b knockout mice showed growth defects due to defective growth hormone 
(GH) signalling. Mice in which both Stat5a and Stat5b were ablated showed additional 
phenotypes, including infertility (Hennighausen & Robinson 2008; Woelfle & Rotwein 
2004) and defects in lymphopoiesis with decreased T cell development during 
embryogenesis and a severe decrease in pro-B and mature B cells in the spleen and 
lymph nodes (Heltemes-Harris et al. 2011; Hoelbl et al. 2006; Li et al. 2007). 
1.5.3 STAT5 in haematopoietic disease 
Constitutively-active STAT5 proteins have been observed in many human 
cancers, especially in haematopoietic neoplasms, such as chronic myelogenous 
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leukaemia, acute lymphocytic leukaemia, erythroleukaemia and various lymphomas 
(Lai & Johnson 2010; Mirmohammadsadegh et al. 2006; Tan et al. 2008; Vafaizadeh 
et al. 2010). However, in addition to its oncogenic activity, STAT5 has also been shown 
to exhibit tumour suppressor activity. 
The oncogenic activity of STAT5 is manifested either through direct 
transcriptional regulation or protein-protein interactions which participate in the growth 
and survival of tumour cells (Basham et al. 2008; Nelson et al. 2006). Activated STAT5 
proteins exert an anti-apoptotic action through upregulation of survival genes, such as 
BCL2, PIM1, and those encoding serine protease inhibitors (Basham et al. 2008; Gatzka 
et al. 2006; Li et al. 2010; Scheeren et al. 2005). Additionally, STAT5 suppresses DNA 
damage response genes, which are responsible for preventing carcinogenesis process in 
early stages. STAT5-mediated inhibition of DNA repair genes results in increased 
incorporation of mutations, which increases the likelihood of progression to tumour 
cells (Gorgoulis et al. 2005; Hou et al. 2007; Mallette & Ferbeyre 2007; Mallette et al. 
2010). However, STAT5 proteins also serve to repress BCL6A expression via 
tetrameric binding sites in its promoter. A number of mutations in DLBCL specifically 
delete these binding sites, facilitating up-regulation of BCL6A expression thereby 
contributing to oncogenesis (Walker, Nelson & Frank 2007). 
1.5.4 Regulation of STAT5 activity 
STAT5 is principally activated as part of the Cytokine receptor-JAK-STAT 
pathway, with major activators being GH (growth hormone), PRL (prolactin), EPO 
(erythropoietin), GM-CSF (Granulocyte-macrophage colony-stimulating factor), G-
CSF (Granulocyte-colony stimulating factor), IL-2, IL-3, IL-4, IL-6 IL-15, CNTF 
(Ciliary neurotrophic factor), LIF (Leukaemia inhibitory factor), and IFNα and IFNγ 
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(Krebs & Hilton 2001; Metcalf et al. 2000; Teglund et al. 1998). BCL6 and STAT5 
have been found to exhibit reciprocal negative regulation, with STAT5 negatively 
regulating BCL6A transcription through specific sites in its promoter (Walker, Nelson 
& Frank 2007), and BCL6A negatively regulating a subset of STAT5 responsive genes 
via overlapping DNA binding motifs (Dent et al. 1997; Lin et al. 2014; Seyfert et al. 
1996). 
1.6 Zebrafish as a model 
1.6.1 Overview 
The zebrafish (Danio rerio) represents a powerful model vertebrate for a wide 
range of biological and medical research applications, particularly the study of 
development and its disruption. This is facilitated by a number of favourable 
characteristics possessed by this organism. Zebrafish are small, reach maturity quickly 
(2-3 month) and have high fecundity, such that each fish can lay more than 200 eggs 
per week making them a highly efficient model. In addition, their external fertilisation 
and transparent embryos greatly augment manipulation and observation at all 
developmental phases, which are broadly conserved with mammals (de Jong and Zon, 
2005). 
1.6.2 Zebrafish genetics and genomics 
Zebrafish shows high levels of genetic conservation with mammals (Kwan & 
North 2017) and considerable genomic resources are available for this organism to 
inform genetic research (Stachura & Traver 2016). Zebrafish is suitable for both 
forward and reverse genetic approaches, which has resulted in the generation of 
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numerous lineage-specific transgenic lines of zebrafish and extensive mutants (Carroll 
& North 2014). 
Zebrafish are particularly amendable to genome editing techniques, especially 
including the so-called clustered regularly interspaced short palindromic repeats 
associated (CRISPR) system. This immune mechanism, which was firstly described in 
Escherichia coli (Barrangou et al. 2007; Grissa, Vergnaud & Pourcel 2007; Ishino et 
al. 1987), has been modified to allow the generation of a short gene-specific ‘guide’ 
RNA. Its co-injection with CRISPR-associated (Cas9) endonuclease into 1 cell 
zebrafish embryos facilitates sequence-specific cleavage of the genomic DNA, with the 
subsequent repair of this lesion resulting in high frequency mutation rates, with these 
mutants enabling functional dissection of the mutated gene (Sertori et al. 2016). 
1.6.3 Haematopoiesis 
Zebrafish haematopoiesis follows the same waves observed in other higher 
vertebrates, comprising primitive and definitive waves. The primitive wave occurs 
approximately between 12-24 hours post fertilization (hpf) in two distinct locations: the 
posterior lateral mesoderm (PLM), particularly in the posterior intermediate cell mass 
(PICM), which give rise to primitive erythroid cells, while primitive macrophages arise 
from the anterior lateral mesoderm (ALM). After 24 hpf, these primitive cells enter the 
circulatory system (Boatman et al. 2013; Orkin & Zon 2008; Travnickova et al. 2015; 
Warga, Kane & Ho 2009). Around this time, the pICM give rise to erythro-myeloid 
precursors (EMP) that generate erythrocytes and neutrophils (Bertrand et al. 2007). 
Around 30 hpf, definitive HSCs emerge from the ventral wall of the dorsal aorta in the 
aorta-gonad-mesonephros (AGM), and enter the circulation at around 36 hpf, where 
they migrate to the caudal haematopoietic tissue (CHT), the equivalent of the 
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mammalian fetal liver, which lies in the ventral region of the embryo tail (Bertrand et 
al. 2010; Kissa & Herbomel 2010; Murayama et al. 2006). Around 3 dpf, lymphoid 
precursors seed the thymus and initiate lymphopoiesis, while at 4 dpf the majority of 
the HSCs migrate to the kidney marrow, the equivalent of the mammalian bone marrow, 
where they provide haematopoietic cells throughout the lifetime of the fish (Jin, Xu & 
Wen 2007; North et al. 2009). 
1.6.4 Haematopoietic transcription factors 
Of particular relevance for this project is the high level of conservation of 
haematopoietic transcription factors between zebrafish and mammals. For example like 
their mammalian counterparts, the transcriptional factors scl, gata2, runx1 and lmo2 
have been found to be crucial for primitive and definitive haematopoiesis in zebrafish 
(Dooley, Davidson & Zon 2005; Patterson et al. 2007; Sood et al. 2010), while c-myb 
is essential for definitive zebrafish haematopoiesis (Soza-Ried et al. 2010; Zhang et al. 
2011). This conservation is also true of lineage-specific transcription factors, with 
gata1 essential for erythrocyte production (Belele et al. 2009; Galloway et al. 2005, 
2008; Lyons et al. 2002; Moriguchi & Yamamoto 2014) and spi1 (pu.1) critical for the 
development of myeloid cells (Hsu et al. 2004; Rhodes et al. 2005). This functional 
equivalence extends to the STAT family of transcription factors, including STAT5, 
with zebrafish stat5.1 shown to regulate several haematopoietic lineages (Lewis, 
Stephenson & Ward 2006). 
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1.7 Project overview 
1.7.1 Rationale 
BCL6A has been recognised as an important transcription factor in the control 
of normal B cell development, as well as its disruption in B cell lymphoma, but with 
emerging roles in the development and/or function of other cell populations. A key 
aspect of BCL6A function is its transcriptional regulation by STAT5, which is activated 
by a number of cytokines in lymphoid cells, while there is evidence that BCL6A 
modifies STAT5 target gene regulation. However, much remains to be learnt about 
BCL6A and the BCL6A/STAT5 functional interaction. 
1.7.2 Hypothesis 
The strong conservation of haematopoiesis and haematopoietic transcription 
factors between zebrafish and mammals underpins the central hypothesis underlying 
this project that analysis of the zebrafish bcl6a gene provides a useful means to further 
investigate the role of BCL6A, including its regulation via STAT5, as well as 
facilitating evolutionary insights. 
1.7.3 Aims 
This Project will investigate this hypothesis via a series of specific aims:  
(i) To characterise the zebrafish bcl6a gene and its regulation by STAT5. 
(ii) To investigate the impact of bcl6a ablation on growth and survival. 
(iii)To characterise the role of bcl6a in blood and immune cell development and 
function.
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1.7.4 Approach 
This Project involves the characterisation of the zebrafish bcl6a gene using 
bioinformatics and analysis of its developmental pattern of expression by whole mount 
in situ hybridisation, with possible regulation via with zebrafish Stat5 proteins explored 
through the use of specific stat5 mutants. The project generates a bcl6a knockout 
zebrafish and analyses the effects of bcl6a ablation on growth, survival, blood and 
immune cell development, with a focus on macrophages, utilising a macrophage-
specific transgenic line.  
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Figure 1.1: Haematopoiesis. 
In the process of haematopoiesis, HSC become committed to increasing specialised 
lineages that ultimate give rise to mature blood and immune cells. Abbreviations: CLP 
(common lymphoid progenitor), CMP (common myeloid progenitor), GMP 
(granulocyte-monocyte progenitor), HSC (haematopoietic stem cell), MEP 
(megakaryocyte-erythroid progenitor), MPP (multipotent progenitor), NK (natural 
killer), RBC (red blood cell). Adapted from (Allman, Aster & Pear 2002). 
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Figure 1.2: BCL6 protein and gene structure. 
BCL6 comprises a highly conserved BTB/POZ domain (pink) at the amino terminus, a 
central PEST domain (yellow), and a zinc finger domain consisting of six zinc fingers 
(green) at the carboxy terminus. This protein is encoded by a gene of 10 exons. There 
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2.1 Materials 
2.1.1 Suppliers 
The following companies supplied reagents and equipment used in this work:  
AGRF, Parkville, Vic, Australia  
Amersham Biosciences, Piscataway, NJ, USA  
Ambion, Austin, TX, USA  
Amresco, Solon, OH, USA  
Applied Biosystems, Warrington, UK  
Astral Scientific, Sydney, NSW, Australia  
BDH Laboratory Supplies, Poole, UK  
Beckman Coulter, Lane Cove, NSW, Australia 
Berthold Technologies, USA 
Bioline, Sydney, NSW, Australia  
Bio-Rad, Hercules, CA, USA  
Chem-Supply, Port Adelaide, SA, Australia  
Eppendorf, Hamburg, Germany  
Gene Codes, Ann Arbor, MI, USA  
Gene Target Solutions, Dural, NSW, Australia  
Gene Tools, Philomath, OR, USA  
GeneWorks, Thebarton, SA, Australia  
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Gilson, Guelph, Canada  
Hitachi, Tokyo, Japan  
Interpath Services, Heidelberg West, Vic, Australia 
Invitrogen, Mount Waverley, Vic, Australia 
Life Technologies, Carlsbad, CA, USA  
Nikon, Tokyo, Japan  
Olympus, Tokyo, Japan  
Promega, Madison, WI, USA  
Qiagen, Melbourne, Vic, Australia  
Roche Molecular Biochemicals, Indianapolis, IN, USA  
Sigma-Aldrich, Sydney, NSW, Australia 
Sigma Genosys products, Texas, USA  
Thermo Scientific, Waltham, MA, USA  
ToolGen, Seoul, South Korea  
VWR, Murarrie, Qld, Australia  
Westlab Group, Ballarat, Vic, Australia  
Zebrafish International Resource Center, Eugene, OR, USA 
2.1.2 Oligonucleotides 
Oligonucleotide primers were synthesised by Sigma Genosys Products (Table 
2.1) for use in polymerase chain reaction (PCR) prior to cloning, reverse transcription 
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(RT)-PCR for evaluating gene expression and high-resolution melt (HRM) analysis of 
mutants (Table 2.1). 
2.1.3 Plasmids 
Plasmids were used to prepare probes of zebrafish genes for whole-mount in 
situ hybridization (WISH) and for luciferase reporter assays (Table 2.2). 
2.2 Methods 
2.2.1 In silico methods 
2.2.1.1 Databases 
Databases used for bioinformatics studies were: National Center for 
Biotechnology Information (NCBI) ((http://www.ncbi.nlm.nih.gov/), Ensembl 
(http://www.ensembl.org), Zebrafish Information Network (ZFIN) (http://zfin.org/), 
and the Universal Protein Resource (UniProt) (http://www.uniprot.org/). 
2.2.1.2 Sequence analysis and alignment 
Sequence analysis, manipulation and assembly were carried out using 
Sequencher version 4.10.0 (Gene Codes). ClustalX 2.1 (Jeanmougin et al. 1998) was 
used to generate sequence alignments, from which phylogenetic trees were generated 
using the Neighbor-Joining algorithm (Saitou & Nei 1987) with replicates of 1000 and 
viewed with NJ plot (http://pbil.univ-lyon1.fr/software/njplot.html) (Perriere & Gouy 
1996) and Treeview 1.6.6 (http://taxonomy.zoology.gla.ac.uk/rod/treeview.html) (Page 
1996). 
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2.2.1.3 Primer design 
Oligonucleotides were designed using the web program Netprimer 
(http://www.premierbiosoft.com/netprimer/netprlaunch/netprlaunch.html). 
2.2.1.4 Statistical analysis 
Statistical analyses were performed using Graph Pad Prism (Version 7) 
software. To determine the statistical significance of various treatments, the unpaired 
independent student t test was employed. Samples with unequal variance employed the 
unpaired independent student t test with Welch’s correction. 
2.2.2 RNA methods 
2.2.2.1 Isolation of total RNA 
Approximately 15-30 zebrafish embryos were homogenized in 1 mL Trizol 
reagent (Life Technologies) and separated into phases with 200 μL of chloroform. After 
a brief incubation at room temperature, the Trizol-chloroform mix was centrifuged at 
12000×g for 10 min at 4ºC. The RNA was extracted from the aqueous phase and 
precipitated by the addition of 500 μL isopropanol and incubation at room temperature 
for 10 min. The RNA was pelleted by centrifugation at 12,000 g for 10 min at 4°C, 
before being washed with 75% (v/v) ethanol and centrifuged at 7,500 g for 5 min at 
4°C. The air dried RNA was resuspended in 30 μL sterile nuclease-free water 
(Amresco). 
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2.2.2.2 Digoxigenin-labelled RNA 
To produce digoxigenin (DIG)-labelled RNA for WISH, 1-2 µg linearized DNA 
or PCR products were mixed with 2.0 µL 10×DIG labelling mix (Roche), 2.0 µL 
10×Transcription buffer, 1.0 µL RNase inhibitor (20 U/µL), 2.0 µL T7 (20 U/µL) or 
SP6 (20 U/µL) polymerase, and the volume adjusted to 20 µL by adding sterile 
nuclease-free water (Amresco). Following incubation at 37°C for 2 h, 2.0 µL of DNase 
I (10 U/µL) was added and the sample incubated at 37°C for a further 15 min to destroy 
the DNA template. The reaction was terminated by the addition of 2.0 µL of 0.2 M 
EDTA (pH 8.0). 
The RNA was purified using G-50 gel filtration exclusion microcolumns (GE 
Health). The column was prepared by brief vortexing followed by centrifugation at 735 
g for 1 min. The labelled RNA was then applied to the column which had been placed 
in a sterile 1.5 mL Eppendorf tube and centrifuged at 735 g for 2 min. The purified 
RNA was then stored at -20°C. 
2.2.2.3 In vitro RNA transcription 
To produce capped RNA and poly A-tailed for injection, a mMessage 
mMachine Kit T7 Ultra (Ambion) was used following the manufacturer's protocol. 
Briefly, up to 1 µg of linearized template DNA, 10 µL 2×NTP/CAP, 2 µL 10×reaction 
buffer and 2 µL enzyme mix containing either T7 or SP6 polymerase was added to a 
final volume of 20 µL and incubated at 37°C for 2 h. To destroy the template DNA, 1 
µL DNaseI was added to the reaction and incubated for 15 min at 37°C. Recovery of 
the RNA was performed using Probe-Quant G-50 micro columns (Amersham). 
Samples were scaled up to 50 µL with sterile nuclease free water (Amresco) and added 
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to the resin bed before subsequent centrifugation at 3,000 rpm for 2 min with the eluate 
stored at -20°C. Alternatively, to produce uncapped guide RNA (gRNA) 
MegaShortscript T7 (Ambion) was used for RNA transcription according to the 
manufacturer’s protocol and gRNA subsequently recovered using the MegaClear kit 
(Ambion) to remove unincorporated ribonucleotides. 
2.2.2.4 Agarose gel electrophoresis 
RNA electrophoresis was performed with a Formaldehyde-Free RNA Gel Kit 
(Amresco). Gels were prepared with 1.2% (w/v) agarose and 1×Formaldehyde-Free 
RNA Gel Solution according to the manufacturer’s instructions, with SYBR safe (Life 
Technologies) added at 1:10000 to enable visualization of RNA. These gels were 
subjected to electrophoresis in Formaldehyde-Free RNA Gel Running Buffer at 100-
110 V for 30 min.  
2.2.3 DNA methods 
2.2.3.1 Reverse transcription 
cDNA was generated with an iScript cDNA Synthesis Kit (Bio-Rad). 500-1000 
ng total RNA was added to 4 µL 5×iScript Reaction mix and 1 µL iScript Reverse 
Transcriptase (U/µL) and the volume adjusted to 20 µL with sterile nuclease-free water 
(Amresco). The reaction mixture was then incubated at 25°C for 5 min and then 42°C 
for 30 min for generation of the cDNA and 85°C for 5 min to denature the reverse 
transcriptase. 
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2.2.3.2 Reverse Transcriptase-Polymerase Chain Reaction 
A 2 µL aliquot of cDNA was used in a PCR reaction containing 12.5 µL Go-
Taq mix (Promega) and 2.5 µL of each primer (10 µM) with the volume adjusted to 25 
µL with sterile nuclease-free water (Amresco). Typical PCR conditions used initial 
denaturation step of 94°C for 2 min, followed by 35 cycles of 94°C for 1 min, 58°C for 
1 min, 72°C for 2 min, and finally 72°C for 10 min. These typical conditions and cycle 
numbers were modified as necessary. 
2.2.3.3 Quantitative Reverse Transcriptase-Polymerase Chain Reaction 
A 2 µL aliquot of cDNA was used in a PCR reaction containing 10 µL 
2xSensiMix™ SYBR® Low-ROX (Bioline) and 0.8 µL each primer (10 µM) with the 
volume adjusted to 20 µL with sterile nuclease-free water (Amresco). Typical PCR 
conditions used an initial denaturation step of 95°C for 10 min, followed by 40 cycles 
of 95°C for 5 sec, 55-58°C for 10 s then 72°C for 25 sec. Fluorescence was read after 
an initial 95°C for 1 min, 55-95°C for 30 s per degree. Samples were run in triplicate 
and data were normalized to β-actin and fold-change was calculated using the ΔΔCt 
method (Livak & Schmittgen 2001). These typical conditions and cycle numbers were 
modified as necessary.  
2.2.3.4 Agarose gel electrophoresis 
Electrophoretic analysis of DNA was performed using 1-3% (w/v) agarose gels 
containing 1×TAE buffer (40 mM Tris-HCl, 190 mM glacial acetic acid, 10 mM 
EDTA; pH 8.0) and 0.006% (v/v) SYBR safe (Life Technologies). These gels were 
subjected to electrophoresis in 1×TAE at 100-110 V for 30-40 min before visualization 
under UV. 
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2.2.3.5 DNA purification 
PCR products were purified using the QIAquick PCR purification kit (Qiagen), 
following the manufacturer’s instructions. DNA fragments were purified from agarose 
gels using the QIAquick gel extraction kit (Qiagen) following the manufacturer’s 
protocol, with variation at step 13 such that the DNA was eluted with 30 µL nuclease-
free water (Amresco). 
2.2.3.6 Restriction enzyme digests 
Plasmid DNA (typically 1-2 μg) was digested using the required restriction 
endonucleases (Roche) for 2 h, following the manufacturer’s directions for incubation 
temperature and buffer. 
2.2.3.7 Plasmid DNA purification 
Plasmid DNA was prepared with a Wizard Plus Minipreps DNA Purification 
System Kit (Promega), following the manufacturer’s recommendations. The protocol 
was varied at steps 1 (centrifugation at 4,000 g for 5 min), as well as steps 5 and 9 
(centrifugation at 13,000 rpm) and step 14 (50 µL nuclease free water used to elute the 
DNA at 13,000 rpm). Alternatively, larger amounts of plasmid DNA were prepared 
with Wizard Plus Midipreps DNA Purification System Kit (Promega) following the 
manufacturer’s recommendations. Variations to the Promega protocol occurred in step 
1 (centrifugation at 4,800 rpm for 5 min), step 5 (centrifugation at 9,800 rpm), and step 
11 (200 μL preheated water was added). DNA was resuspended in 50-200 μL sterile 
distilled water. 
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2.2.3.8 Genomic DNA extraction 
Genomic DNA was extracted from embryos or fin clips using 30 µL 
QuickExtract solution (Epicentre). Samples were incubated at 68°C for 2 min before 
vortexing for 30 s and incubating at 98°C for 2 min. Samples were again vortexed for 
30 s and then centrifuged at 13,000 rpm for 5 min at 4°C. 
2.2.3.9 High resolution melt analysis 
High-resolution melt (HRM) was performed after PCR using a 10 μL reaction 
containing 5 μL Precision Melt Supermix (Biorad), 200 nM each primer (sense and 
anti-sense), 3.5 μL nuclease free water and 0.5 μL genomic DNA to detect potential 
mutations, which was were subjected to PCR with CFX96 with an initial denaturation 
step 95°C for 2 min, followed by 45 cycles 95°C for 10 sec, primer (Tm °C), for 30 s 
and 72°C for 30 s. This was followed by 95°C for 30 s, 60°C for 1 min, then 0.2°C 
temperature increments from 65-95°C for 10 s/step and fluorescence measured and 
analysed using Precision Melt Analysis Software 1.2 (Bio-Rad). 
2.2.3.10 DNA sequencing 
Sequencing was carried out on double-stranded plasmid DNA or PCR products 
of 100-1000 bp. Reactions contained 3-75 ng template DNA and 0.83 µM 
oligonucleotide primer in 12 µL reactions adjusted with sterile nuclease-free water 
(Amresco) and sent to the Australian Genome Research Facility for sequence analysis. 
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2.2.3.11 Next generation (Next Gen) sequencing (NGS) 
RNA was extracted from 5 dpf embryos using RNeasy Plus Mini kit (Qiagen) 
following manufacturer’s instructions. RNA was delivered to AGRF on dry ice where 
the quality of the RNA was confirmed using Agilent 2100 bioanalyzer, with the NGS 
library prepared using TruSeq RNA library Prep Kit v2 (Illumina). Finally the 
sequencing was performed using a a HiSeq 2500 system (Illumina) with 100 bp single 
end read.  
RNAseq reads were trimmed to remove Illumina adaptor sequences and low 
quality ends using Trimmomatic v0.36 (Bolger, Lohse & Usadel 2014). Trimmed reads 
were mapped to the coding sequences (cds) of the Danio rerio reference genome: 
ftp://ftp.ncbi.nlm.nih.gov/genomes/refseq/vertebrate_other/Danio_rerio/reference/GC
F_000002035.6_GRCz11/ using BBmap v38.33 (2). Mapped read counts per sample 
were tabulated using a custom Python script and statistically analysed for differential 
expression using EdgeR (Robinson, McCarthy & Smyth 2010) and ALDEX2 
(Fernandes et al. 2013). 
2.2.4 Bacterial methods 
2.2.4.1 Bacterial strains and media 
E.coli strain XL 10-Gold endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte 
Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 tetR F'[proAB lacIqZΔM15 Tn10(TetR Amy 
CmR)] was used for plasmid propagation. Clones were grown in 2×YT medium (1.6% 
(w/v) tryptone, 1.0% (w/v) yeast extract, 0.5% (w/v) NaCl) in the presence of 
appropriate antibiotic (typically 100 µg/ml ampicillin (Amp)), to enable selection of 
plasmids. Solid media contained 1.6% (w/v) agar. 
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E. coli expressing green fluorescent protein (GFP) (#25922GFP, ATCC) 
propagated in pUCP18-MCSgfpmut3 vector (Palazzolo et al. 2005). The E. coli – GFP+ 
bacteria was grown overnight in tryptic soy media and the CFU was estimated by 
determining the broth absorbance at 600 nm. The broth was then centrifuged at 3000 g 
at 4º C for 15 min and the bacterial pellet resuspended in sterile PBS at a concentration 
of 5×107 CFU/mL (Wang et al. 2011). 
2.2.4.2 Competent cells 
XL 10-Gold cells were grown in 50 mL LB at 37oC with shaking at 200 rpm 
until OD600 reached 0.3-0.6. Cultures were harvested by centrifugation at 4000 rpm 
for 20 min at 4°C. The supernatant was removed and the pellet resuspended in 15 mL 
of ice-cold buffer RF1 (160 mM KCL, 50 mM MnCl2.4H2O, 30 mM CH3CO2K, 10 
mM CaCl2.2H2O, 15% (v/v) glycerol) at pH 5.8. The suspension was incubated on ice 
for 15 min and centrifuged at 4,000 rpm for 10 min at 4°C. The pellet was resuspended 
in 5 mL ice cold buffer RF2 (10 mM MOPS, 20 mM KCl, 70 mM CaCl2.2H2O, 15% 
(v/v) glycerol) and incubated on ice for 15 min. The cells were aliquoted (100 µL) and 
frozen with liquid nitrogen for storage at -80°C. 
2.2.4.3 Ligation and transformations 
Linear PCR products were ligated using the pGEM-T and pGL3 easy vector 
system (Promega) following the manufacturer’s recommendations and using a 2:1 ratio 
of DNA:Vector and an overnight incubation at 4oC. Competent XL 10-Gold cells were 
removed from the -80°C freezer and thawed on ice. An aliquot of 2-5 µL ligation 
solution was added to 100 µL competent cells and incubated on ice for a further 15 min 
before a 45 s heat-shock at 42°C that was terminated by placing the tube on ice for 3 
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min. Following this, a pre-warmed 800 µl aliquot of 2×YT broth was added and the 
cells were incubated at 37ºC for 1 h with shaking at 200 rpm. Cells were plated onto 
2×YT plate media containing appropriate antibiotic with 30 mg/mL 5-bromo-4-chloro-
3-indolyl β-D-galactopyranoside (X-gal) in the care of pGEM-T ligation, and once dry 
were incubated overnight at 37°C and visually screened for blue/white colonies where 
appropriate.  
2.2.5 Cell culture methods 
2.2.5.1 Cells and transfection 
Human embryonic kidney (HEK) 293T cells were maintained in DMEM media 
at 37°C and 5% (v/v) CO2 in an air-jacketed incubator. They were transiently 
transfected at 50-80% confluence using 3:1 ratio of Lipofectamine 2000 (Invitrogen) 
reagent (µl) to DNA (µg) respectively with relevant luciferase reporter vectors. 
Transfection complexes containing 200 μL serum free DMEM media, 1 μg DNA, and 
3 μL Lipofectamine were incubated at RT for 15 min and then added to the cells in a 
drop-wise manner. After an incubation time of 48 h post-transfection, cells were 
harvested for analysis. 
2.2.5.2 Luciferase assay 
Lysates were harvested from transfected HEK293T cells using a Dual 
Luciferase Kit (Promega), following the manufacturer’s recommendations. Samples 
were subsequently analysed using a single tube luminometer (Berthold Technologies 
Lumat, LB 9507) with Firefly luciferase reporter activities normalized to the level of 
control Renilla luciferase activity. 
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2.2.6 Zebrafish methods 
2.2.6.1 Fish maintenance and embryo collection 
Adult zebrafish were maintained in an Aquatic Habitats aquarium system at 
28.5°C on a 14 h/10 h light/dark cycle and fed twice daily. Embryos were manually 
spawned and maintained in the incubator at 28.5°C in a petri dish containing aquarium 
water and 0.00005% (w/v) methylene blue (Sigma-Aldrich). At 8 hours post 
fertilization (hpf), this was replaced with aquarium water containing 0.003% (w/v) 1-
phenyl-2-thio-urea to inhibit pigmentation to enhance embryo transparency. Embryos 
were collected at appropriate time points, and anesthetized with 0.4 mg/mL benzocaine 
before fixation with 4% (w/v) paraformaldehyde (PFA) in phosphate-buffered saline 
(PBS). All experiments were performed under Deakin University Animal Welfare 
Committee guidelines.  
2.2.6.2 Microinjection and mutant generation 
Injection needles were drawn on a Flaming-Brown micropipette puller model 
P-87 (Sutter Instruments) using a heat setting of 339, pull 45, velocity 80 and time 150, 
from a 1.0 mm capillary (SDR Clinical Technologies), bent by flaming and loaded 
using pipette tips with mRNA diluted to 300 ng/μL in 1×Danieau buffer (58 mM NaCl, 
0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM CaCl2, 5.0 mM HEPES; pH 9) containing 1% 
(w/v) phenol red or 100 pg/nL mRNA of Cas9 and 12.5 ng/µL of gRNA for CRISPR. 
Needles were mounted in a Narishige MN-151 micromanipulator attached to a Nikon 
SMZ 645 dissecting microscope. Embryos at the 1 cell stage were held with 
watchmakers’ forceps and the needle positioned so as it entered the yolk between the 
individual cells. Typical injection conditions included pulse duration of 0.3 s and a gas 
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pressure of 400 kPa. Embryos were subsequently allowed to develop on a warming tray 
at 28°C. The zebrafish bcl6a gene was targeted using genome editing with 
CRISPR/Cas9. Embryos were injected with guide RNA (gRNA) designed to a region 
of exon 3 encoding the BTB/POZ domain along with Cas9-encoding mRNA and raised 
to adulthood. Potential founders were identified with high-resolution melt (HRM) 
analysis of PCR products spanning the targeted region. These were outcrossed two 
times to wild-type fish to remove off-target mutations before in-crossing. Sequence 
analysis identified a bcl6a allele (mdu21) that harboured a combined 28 bp deletion and 
59 bp insertion. 
2.2.6.3 Embryo fixation 
Embryos were euthanized using 0.4 mg/mL benzocaine (Sigma) prior to 
fixation in 4% (w/v) PFA in PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO, 1.47 
mM KH2PO4) (PFA/PBS). Fixed embryos were stored at 4°C for at least 1 day, after 
which embryos were dehydrated with 100% (v/v) methanol for long-term storage at -
20°C.  
2.2.6.4 Bacterial infection assay 
Embryos at 4 dpf (n>60 mixed progeny for each time point, repeated twice) 
were injected with 2-5 nl ~ 5 x 107 CFU/mL E. coli expressing GFP into the venous 
return, with bacteria visualized by fluorescence microscopy. The survival of infected 
embryos was monitored by regular visual inspection. 
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2.2.6.5 Wound healing assay 
Wound-healing assays were performed on 3 dpf embryos (n>20 mixed progeny) 
by excising the end of the caudal tail fin with a scalpel (blade number 21) after 
anaesthesia with 0.1 mg/mL benzocaine, as described (Hall et al. 2007) with the number 
of migrating cells counted up to 8 h after wounding. 
2.2.6.6 Whole mount in situ hybridization (WISH) 
Fixed embryos (n>25 mixed progeny for each time point), repeated twice were 
rehydrated via a series of 5 min washes in 50% (v/v) methanol, 30% (v/v) methanol 
and PBS-T (PBS plus 0.1% Tween-20) before refixing for 20 min in 4% (v/v) PFA/PBS 
followed by 3 washes in PBS-T. Embryos older than 26 hpf were then incubated at 
room temperature in PBS containing proteinase K, 24-36 hpf with 10 µg/mL proteinase 
K for 10 min, 36 hpf-10 dpf with 20 µg/mL proteinase K for 30 min. Hybridization 
involved digoxigenin-labelled antisense RNA probes transcribed from appropriately 
linearized plasmids. Embryos were incubated in 500 µL HYB- (50% (v/v) formamide, 
5×sodium chloride/sodium citrate (SSC), 0.1% (v/v) Tween-20) for 5 min at 70°C, 
which was replaced with 500 µL HYB+ (HYB- containing 5 mg/mL ribonucleic acid, 
0.05 mg/mL heparin (Sigma)) which was incubated at 70°C for at least 3 h. Embryos 
were bathed in 300 µL probe solution (1/50–1/300 dilution in HYB+) and incubated at 
70°C overnight. Probes solutions were removed following the incubation and the 
embryos were washed in 50% (v/v) formamide/2×SSC-T for 30 min and 60 min at 
70°C. Embryos were then washed for 15 min in 2×SSC-T followed by 2 × 15 min 
washes in 0.2×SSC-T also at 70°C. This was followed by 3 × room temperature washes 
in PBS-T followed before incubation in blocking solution (0.02% (w/v) bovine serum 
albumin (BSA), 5% (v/v) fetal calf serum (FCS) in PBS-T) for 2 h at room temperature. 
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Following the incubation, embryos were placed into blocking solution with (0.15 U/μL) 
of alkaline phosphatase (AP) conjugated anti-DIG antibody (Roche) and incubated at 
4°C overnight. Embryos were washed 6 × 15 min in PBS-T at room temperature with 
gentle rocking and then 3 × 5 min washes in staining buffer (0.1 M Tris pH 9.5, 0.05 M 
MgCl2, 0.1 M NaCl, 0.1% (v/v) Tween 20) containing 25 μg/mL levamisol. Following 
this, embryos were stained in buffer containing (0.225 mg/mL nitroblue tetrazolium 
(NBT) and 0.175 mg/mL 5-bromo, 4-chloro, 3-indolyl phosphate (BCIP)) at room 
temperature in the dark for 4 h-3 d, but normally overnight. Embryos were finally rinsed 
in PBS-T and fixed in 4% PFA/PBS when stained to an appropriate extent. The area of 
expression in the stained embryos were measured in micrometres using ImageJ 
software.  
2.2.6.7 High resolution WISH 
Fixed embryos (n>25 mixed progeny for each time point) were rehydrated via 
a series of 5 min washes in 75% (v/v) methanol, 50% (v/v) methanol, 25% (v/v) 
methanol and PBS before 4 × 5 min washes in PBS-T. Embryos were then incubated at 
room temperature in PBS-T containing 10 µg/mL proteinase K for 30 s (blastula and 
gastrula), 1 min (early somitogenesis), 5 min (late somitogenesis), or 15 min (24hpf), 
36 hpf -10 dpf or with 20 µg/mL proteinase K for 30 min (36 hpf -10 dpf) before fixing 
for 20 min in 4% (v/v) PFA/PBS followed by 5 × 5 min washes in PBS-T. Embryos 
were incubated in 800 µL HYB+ mix (50% formamide, 5 × SSC, 0.1% Tween-20, 9.2 
µL/mL citric acid pH 6, 50 µg/mL heparin and tRNA 500 µg/mL) for 2-5 h. Embryos 
were then bathed in 200 µL of probe solution (1/50–1/300 dilution in HYB+ mix) and 
incubated at 70°C overnight. Probes solution was removed and embryos washed briefly 
in 100% HYB– (50% formamide, 5×SSC, 0.1% Tween-20, 9.2 µL/mL citric acid pH 
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6) and then for 15 min in 75% HYB–/25% 2×SSC, 50% HYB–/50% 2×SSC, 25% 
HYB–/75% 2×SSC and 2×SSC, then twice in 0.2×SSC 30 min, then 10 min in 75% 
0.2×SSC/25% PBS-T, 50% 0.2×SSC/50% PBS-T, 25% 0.2×SSC/75% PBS-T and 
PBS-T. Embryos were then incubated in PBS-T/2% sheep serum/2 mg/ml BSA at RT 
for 3 h then in antibody solution (1:5000 anti-DIG antibody in PBS-T 2% sheep serum 
and 2 mg/ml BSA pre-absorbed against embryos) at 4°C overnight with agitation. 
Embryos were rinsed in PBS-T then washed 6 × 15 min in PBS-T at room temperature 
with gentle rocking and then 3 × 5 min washes in staining buffer (0.1 M Tris pH 9.5, 
0.05 M MgCl2, 0.1 M NaCl, 0.1% (v/v) Tween 20) containing 25 μg/mL levamisol. 
Following this, embryos placed in staining buffer containing 0.225 mg/mL NBT) and 
90.175 mg/mL BCIP at room temperature in the dark for 4 h-3 d, but normally 
overnight. Embryos were finally rinsed in PBS-T and fixed in 4% PFA/PBS when 
stained to an appropriate extent. 
2.2.6.8 Imaging 
Embryos were visualised using a MVX10 microscope (Olympus) with stage 
lighting provided using LG-PS2 fibre optics light source (Olympus). Digital images 
were recorded using CellSens Dimension 1.6 software (Olympus) and DP72 camera 
(Olympus). 
2.2.6.9 Fin clipping 
Individual zebrafish were placed 20 μg/mL benzocaine in aquarium water until 
their gills stopped moving, transferred to a glass slide and the tail fin tip cut with a 
number 10 scalpel blade. The zebrafish was placed in aquarium water to recover.
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2.2.6.10 Fish measurement 
Embryos and juvenile fish subjected to fixation with PFA and adult fish treated 
with 20 μg/mL benzocaine and lightly dried were imaged on an MVX10 microscope 
(Olympus). From the image, area of expression was determined with ImageJ, eye 
diameter, fish length and width were directly quantified in micrometres using a ruler as 
guiding reference placed adjacent to the fish during imaging. Swim bladder inflation in 
juveniles was assessed under a light microscope (Shu et al. 2016). 
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Table 2.1 Primers used in this study. 
 
Primer Description Use Oria Sequence 5’-3’ bp 
AW024 β-actin  RT-PCR S TGGCATCACACCTTCTAC 18 
AW025 β-actin  RT-PCR AS AGACCATCACCAGAGTCC 18 
AW216 T3 sequencing N/A AATTAACCCTCACTAAAGGGA 21 
AW217 SP6 sequencing N/A AATTAGGTGACACTATAG 18 
AW218 T7 sequencing N/A TAATACGACTCACTATAGGG 20 
AW269 M13 rvs PCR AS CAGGAAACAGCTATGAC 17 




promoter fwd  
PCR S TGGTCCACAGATTTGAAGAGGC 22 
AW1480 bcl6a 
promoter rvs  
PCR AS ACAACAAAACCAAAACGTCACG 22 
AW1510 bcl6a gRNA4 
fwd 
HRM S TAGGTCCAGACTGATGGCGTTC 22 
AW1511 bcl6a gRNA4 
rvs 
HRM AS AAACGAACGCCATCAGTCTGGA 22 
AW1533 bcl6a fwd PCR S GCCACTTTCTCTCCCCACG 19 
AW1534 bcl6a rvs PCR AS CTGAAAACTCCACAAAACGCC 21 
AW1580 bcl6a gRNA7 
oligo 1 fwd 
CRISPR S TAGGACGCGTCCATTAGAGAGG 22 
AW1581 bcl6a gRNA7 
oligo 2 rvs 
CRISPR AS AAACCCTCTCTAATGGACGCGT 22 
AW1582 bcl6a gRNA8 
oligo 1 fwd 
CRISPR S TAGGCGTTTTGTGGAGTTTTCA 22 
AW1583 bcl6a gRNA8 
oligo 2 rvs 
CRISPR AS AAACTGAAAACTCCACAAAACG 22 
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Table 2.2 Plasmids used in this study. 
 
Plasmid Vector Gene Application 





pA248 pGEM-T mpo 
(zebrafish) 
WISH 
pA249 pSport l-plastin 
(zebrafish) 
WISH 
pA451 pCR2.1 rag1 
(zebrafish) 
WISH 
pA455 pBS KS ikaros 
(zebrafish) 
WISH 
pA1057 pBSus bcl6a 
(zebrafish) 
WISH 









 Characterisation of zebrafish bcl6a and its 
regulation
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3.1 Introduction 
The B cell lymphoma 6 (BCL6) proteins are well conserved across a range of 
different species. This includes vertebrates, which have been shown to possess distinct 
but highly-related BCL6A and BCL6B proteins (Okabe et al. 1998), as well as 
invertebrates, typified by a BCL6-related protein identified in fruit-fly that is referred 
to as Ken & Barbie (Ken) (Arbouzova, Bach & Zeidler 2006). 
BCL6 proteins consist of three conserved domains. At the N-terminus is a 
BTB/POK domain responsible for protein-protein interactions and complex formation 
with co-repressors (Basso & Dalla-Favera 2010). This is followed by a central PEST 
domain that is a target for posttranslational modification, which controls protein 
stability and interactions with transcriptional regulators (Basso & Dalla-Favera 2012; 
Niu, Ye & Dalla-Favera 1998). At the C-terminus is a zinc finger domain containing 
an array of six zinc fingers that bind to specific DNA sequences (Brayer & Segal 2008).  
BCL6A is negatively regulated by STAT5 via a specific tetrameric site in its 
promoter (Walker, Nelson & Frank 2007). The STAT5 binding region of the BCL6A 
gene is frequently mutated in a range of human cancers leading to overexpression of 
BCL6A (Huang, Hatzi & Melnick 2013; Walker, Nelson & Frank 2007). 
The aim of this Chapter was to identify and characterise the zebrafish bcl6a 
gene. This involved investigating its conservation and evolutionary relationships, as 
well as analysing its pattern of embryonic expression and the dependence of this on 
zebrafish Stat5. 
Chapter 3 
  48 
3.2 Identification and characterisation of BCL6-related genes in 
zebrafish 
Bioinformatic analysis of zebrafish gene databases using tBLAST with human 
BCL6A and BCL6B sequences identified putative homologues for each gene, 
designated bcl6a and bcl6b, respectively, as well as an additional related sequence that 
was named bcl6ab. Homologues of all three genes were also present in another teleost 
fish, torafugu (Takifugu rubripes). Analysis of surrounding genes using Genome 
Browser identified conserved syntenic relationships amongst BCL6A genes, with the 
adjacent genes LPP and TPRG1, TP63 conserved between mammalian and zebrafish 
genomes (Figure 3.1A). Similarly, BCL6B genes shared adjacent SLC16A13, ACADVL 
and DVL2 genes across mammals and fish. The fish bcl6ab genes also showed 
conserved synteny with each other, but not with bcl6a or bcl6b genes. Collectively, this 
suggests zebrafish bcl6a and bcl6b are orthologues of mammalian BCL6A and BCL6B, 
respectively, while bcl6ab represents a fish-specific duplicate. 
The encoded zebrafish and torafugu Bcl6a, Bcl6b and Bcl6ab proteins, along 
with human and mouse BCL6A and BCL6B, fruit-fly Ken and the related MYNN 
protein homologues from human, mouse, zebrafish and torafugu were aligned with 
ClustalW and a phylogenetic tree generated using the Neighbor-Joining algorithm 
(Saitou & Nei 1987) (Figure 3.1B). This analysis revealed that BCL6A proteins from 
human and mouse formed a clade with zebrafish and torafugu Bcl6a proteins, supported 
by a strong bootstrapping value. The novel piscine Bcl6ab sequences formed a larger 
clade with the BCL6A sequences, while vertebrate BCL6B-related sequences were 
more divergent, with mammalian and fish proteins forming separate sub-clades. The 
invertebrate Ken protein was the most divergent of the BCL6-related sequences. 
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3.3 Conservation of zebrafish bcl6a gene and encoded protein 
Alignment of the human BCL6A and zebrafish Bcl6a proteins using ClustalW 
confirmed the presence of conserved BTB/POZ, PEST and zinc finger domains, which 
showed 77%, 35% and 96% identity, respectively (Figure 3.2A). Notably, the last three 
of the six C2H2-type zinc fingers showed 100% amino acid identity. 
Comparison of the genomic and mRNA sequences using Sequencher enabled 
the elucidation of the intron-exon structure of the zebrafish bcl6a gene (Figure 3.2B). 
The human BCL6A and zebrafish bcl6a genes showed a strongly conserved splicing 
pattern, with coding exons covering equivalent regions of the respective proteins 
between the two species, as well as a non-coding exon in the proximal promoter region. 
Nucleotide sequence alignment between zebrafish and human proximal promoters 
using ClustalW revealed a highly conserved 82 bp in this region containing tetrameric 
STAT5 binding sites (termed α, β, γ and δ), present, with only two nucleotide 
differences and none within the core TTCNNNGAA STAT5 recognition sequences. 
3.4 Expression of zebrafish bcl6a 
The embryonic expression pattern of zebrafish bcl6a was investigated by high 
resolution WISH on staged wild-type embryos that were fixed up to 7 days post-
fertilization (dpf) with sense and anti-sense bcl6a probes. Staining was observed by 
light microscopy with the anti-sense probe from 10 hours post-fertilization (hpf) to 7 
dpf (Figure 3.3A, C-L), while none was observed with the sense control at this time 
point (Figure 3.3B) or any stage later in development (data not shown). Early bcl6a 
expression was in the anterior lateral mesoderm (ALM) and the posterior lateral 
mesoderm (PLM), which continued until 24 hpf (Figure 3.3A,C-F). From 36 hpf, bcl6a 
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was found to be expressed in the retina, cerebellum and medulla (Figure 3.3G-H), that 
continued until 7 dpf at a lower level at these locations (Figure 3.3I-L). From 5 dpf 
bcl6a expression was also detected in the developing thymus (Figure 3.3I-L). 
3.5 Role of STAT5 in bcl6a expression 
To investigate the regulation of bcl6a expression by zebrafish Stat5, wild-type, 
stat5.1-/- and stat5.2-/- embryos (C. Liongue & A. C. Ward, unpublished) were subjected 
to WISH with anti-sense bcl6a and imaged by light microscopy. Both stat5.1-/- and 
stat5.2-/- embryos showed more intense bcl6a expression in the retina, cerebellum and 
medulla at both 5 dpf and 7 dpf compared to wild-type embryos but expression in the 
thymus was equivalent (Figure 3.4A-L). Additional expression was seen in the gill and 
lateral neuromasts. In each case, loss of stat5.2 produced the most pronounced increase. 
Analysis of Next Gen sequencing data of the transcriptomes of stat5.1-/- and stat5.2-/- 
embryos revealed a statistically-significant increase in the expression of bcl6a (and 
bcl6ab) in stat5.2-/- embryos (Figure 3.4M). To further investigate the role of STAT5, 
the tetrameric STAT5 binding sites from the zebrafish bcl6a promoter were cloned into 
the pGL3 luciferase reporter (Figure 3.4N). When transfected into HEK293 cells, the 
presence of these sites caused significant repression of the endogenous luciferase 
expression compared to the original pGL3 plasmid (Figure 3.4O). 
3.6 Discussion 
3.6.1 Overview 
Mammalian BCL6A, and the closely-related BCL6B, are transcriptional 
repressors consisting of BTB/POZ, PEST and zinc finger domains (Basso & Dalla-
Favera 2010). BCL6A has been shown to have an antagonistic relationship with 
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STAT5, whereby BCL6A binds to overlapping promoter sequences to STAT5 thereby 
blocking its activity (Lin et al. 2014), while STAT5 acts as a repressor of BCL6A 
expression (Walker, Nelson & Frank 2007). This relationship is conserved in fruit-fly 
with respect its BCL6 homologue, Ken, and its STAT homologue, Marelle (Stat92E) 
(Hombria & Sotillos 2006). 
This Chapter aimed to further our understanding of BCL6A, its evolution, 
expression and regulation. Firstly, identified a conserved BCL6A gene orthologue in 
zebrafish, bcl6a, which contained signature tetrameric STAT5 sites in its promoter 
elements, as well as additional related genes, bcl6b and bcl6ab. Secondly, investigated 
the expression of zebrafish bcl6a during embryogenesis and examined the role of 
STAT5 in bcl6a expression. 
3.6.2 Conservation of bcl6a 
BCL6A homologues are highly conserved, with murine BCL6A 95% identical 
to its human BCL6A counterpart (Fukuda et al. 1995). This Chapter identified a clear 
zebrafish bcl6a orthologue on the basis of phylogenetic and syntenic analysis. The 
encoded protein showed overall identity of 61% to the corresponding human BCL6A, 
with equivalent BTB/POZ, PEST and zinc finger domains, the latter showing 96% 
identity. A bcl6a gene was cloned previously from torafugu, another teleost fish, with 
the encoded protein showing a similar level of identity to the mammalian BCL6A 
proteins (Ohtani, Miyadai & Hiroishi 2006). This high conservation indicates a likely 
conserved function across vertebrates and particular of target DNA sequences.  
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3.6.3 Expression of bcl6a 
Analysis of bcl6a expression during zebrafish embryogenesis revealed dynamic 
expression in haematopoietic and neuro-sensory tissues. Intense bcl6a expression was 
first observed at 10 hpf in the ALM and the PLM during early embryogenesis, which 
represent sites of primitive haematopoiesis in the zebrafish (Bertrand & Traver 2009). 
Later from 5 dpf, bcl6a was expressed in the thymus, the site of T lymphocyte 
development (Murayama et al. 2006). Additionally, bcl6a was expressed in regions of 
the brain and retina from 36 hpf. This is consistent with a recent study that found that 
bcl6a expression in the zebrafish eye (Lee, Lee & Gross 2013). Collectively, this 
expression pattern suggests that bcl6a may play roles in both haematopoietic and non-
haematopoietic cells. 
3.6.4 STAT5-mediated regulation of bcl6a expression 
Bioinformatic analysis of the zebrafish bcl6a promoter region revealed almost 
complete conservation of the tetrameric STAT5 binding sites found in the BCL6A 
promoter. This region was found to confer a strong repressive effect in an in vitro 
luciferase reporter assay. In addition, significant upregulation of bcl6a expression was 
observed in stat5.2-/- embryos, particularly with neuro-sensory tissues, which included 
expression in lateral neuromasts that was not evident in wild-type embryos. This 
identifies Stat5.2-mediated negative regulation of bcl6a during embryogenesis, almost 
certainly through the tetrameric STAT5 binding sites within its promoter. This is 
consistent with the high conservation of both STAT5 and BCL6A between zebrafish 
and humans and collectively indicates a conserved mode of regulation across 
vertebrates. 
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3.6.5 Conclusion 
The findings presented in this Chapter have together identified a zebrafish bcl6a 
gene with conserved structure and regulation, encoding a protein with high identity to 
human BCL6A. This suggest that zebrafish bcl6a function is likely to be conserved, 
with roles elucidated in zebrafish therefore relevant for mammals. Moreover, the 
embryonic expression pattern suggests roles in both haematopoietic and non-
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Figure 3.1: Conservation of BCL6 across selected species. 
A. Synteny analysis of BCL6-related genes. Arrangement of the gene neighbourhood 
surrounding BCL6-related gene loci from human (Homo sapiens, hs), mouse (Mus 
musculus, mm), zebrafish (Danio rerio, dr) and torafugu (Takifugu rubripes, tr). The 
BCL6-related genes are in black, neighbouring genes conserved between mammals and 
fish in green, between mammals in blue and between fish in red, with all other genes in 
grey. 
B. Phylogenetic analysis of BCL6-related proteins. The amino acid sequences of fruit-
fly Ken and Barbie (Ken) was aligned with the BCL6A-related sequences of human 
(hs), mouse (mm), zebrafish (dr) and torafugu (tr), and the MYNN-related sequences 
from human, mouse and torafugu using Clustal W. This was used to construct a 
phylogenetic tree using the Neighbour-Joining method with 1000 replicates, with 
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Figure 3.2 Conservation of BCL6A between human and zebrafish. 
A. Conserved domains in BCL6A proteins. Human BCL6A and zebrafish Bcl6a were 
aligned using Clustal X software, with specific domains highlighted (BTB/POZ in pink, 
PEST in yellow, zinc fingers in green). Conserved residues between the two sequences 
are indicated (identical *, highly similar :, similar .). 
B. Conserved BCL6A gene structure. Schematic diagram of human BCL6A and 
zebrafish bcl6a loci, with exons shown as boxes and introns as lines. Regions 
corresponding to the promoter (grey) or those encoding the BTB/POZ (pink), PEST 
(yellow) and zinc finger (green and numbered) domains are indicated. Dotted lines 
highlight the promoter region which is expanded below, containing tetrameric STAT5 
binding sites (α, β, γ and δ), with conserved nucleotides indicated with asterisks. 
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Figure 3.3 Expression of bcl6a during zebrafish embryogenesis. 
Wild-type embryos were subjected to WISH for bcl6a expression with sense (control) 
and anti-sense (bcl6a) probes as indicated at 10 hpf (A,B), 16 hpf (C,D), 24 hpf (E,F), 
36 hpf (G,H), 5 dpf (I,J) and 7 dpf (K,L), showing lateral (A-C,E,G,I,K) and dorsal 
(D,F,H,J,L) views. Representative images of n>25 mixed progeny, repeated twice. 
ALM = anterior lateral mesoderm, C = cerebellum, M = medulla, PLM = posterior 
lateral mesoderm, R = retina, T = thymus. 
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Figure 3.4 Role of Stat5 in bcl6a expression. 
A-L. WISH analysis of bcl6a expression in wild-type (wt) (A,D,G,J), stat5.1-/- 
(B,E,H,K) and stat5.2-/- (C,F,I,L) embryos at 5 dpf (A-F) and 7 dpf (G-L) in lateral (A-
C, G-I) or dorsal view (D-F, J-L). Representative images of n>25, repeated twice. C = 
cerebellum, G = gills, L = lateral neuromasts, M = medulla, R = retina, T = thymus.  
M. Expression of bcl6a, bcl6b and bcl6ab from NextGen sequencing of wild-type (wt) 
and stat5.1-/- and stat5.2-/- fish. 
N. Schematic diagram of luciferase reporter constructs, including the control pGL3 in 
which luciferase is under control of SV40 regulatory elements, and pGL3-bcl6a that 
includes the tetrameric STAT5 sites from the zebrafish bcl6a promoter. 
O. Relative luciferase activity of the indicated luciferase reporter plasmids in HEK 
293T cells. Normalised luciferase activity was determined and expressed as the mean 
± SEM. HEK 293T cells line transfected with  wild-type STAT5 were used as a control.
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 Role of bcl6a in zebrafish development, 
growth and survival 
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4.1 Introduction 
BCL6A has been demonstrated to influence postnatal growth and survival. 
Bcl6a knockout mice are smaller with a low survival rate (Yoshida et al. 1999), 
displaying a fatal systemic inflammatory phenotype resulting from aberrant interaction 
of T helper cells and macrophages (Basso & Dalla-Favera 2010; Hatzi & Melnick 
2014). BCL6A has also found to play a reciprocal role with STAT5 in regulating growth 
hormone-responsive genes (Chen et al. 2009). 
As described in Chapter 3, there is strong conservation between zebrafish and 
mammalian BCL6A genes and encoded proteins. Therefore, it was hypothesized that 
ablation of the zebrafish bcl6a gene may shed new light on the role of BCL6A in 
vertebrates. The aim of this Chapter was to use genome editing to generate zebrafish in 
which the bcl6a gene is functionally ablated and characterise their phenotypes including 
any impacts on overall development, growth and survival. 
4.2 Generation of bcl6a knockout zebrafish 
The zebrafish bcl6a gene was targeted using genome editing with 
CRISPR/Cas9. Embryos were injected with a guide RNA (gRNA) designed to a region 
of exon 3 encoding the BTB/POZ domain (Figure 4.1A-B) along with Cas9-encoding 
mRNA and raised to adulthood. Potential founders were identified with high-resolution 
melt (HRM) analysis of PCR products spanning the targeted region. These were 
outcrossed two times to wild-type fish to remove off-target mutations before in-
crossing. Sequence analysis identified a bcl6a allele (mdu21) that harboured a 
combined 28 bp deletion and 59 bp insertion (Figure 4.1C). Using Sequencher, this 
allele was predicted to encode a protein that shares the first 83 amino acids with the 
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wild-type protein, and then encodes 29 amino acids of unrelated sequence before a stop 
codon is reached. Since this represents only part of the BTB/POZ domain and none the 
PEST or zinc finger domains, it is anticipated that this mutant protein would be non-
functional. 
4.3 Analysis of bcl6a knockout zebrafish 
4.3.1 Embryonic development 
The progeny of bcl6awt/mdu21 in-crosses were imaged by light microscopy 
visually, with no evidence of developmental perturbation during embryogenesis 
observed in mixed groups, which should contain 25% bcl6amdu21/mdu21 embryos (Figure 
4.2A-D), or in individually genotyped embryos (Figure 4.2E). A previous report using 
anti-sense morpholinos to knockdown bcl6a suggested optic cup formation was 
affected (Lee, Lee & Gross 2013). However, no evidence of this was observed in 
bcl6awt/mdu21 in-cross progeny. 
4.3.2 Post-embryonic growth 
Further investigation of fish length and width by imaging and analysis with 
ImageJ revealed that juveniles at 21 dpf showed large and distinct differences in size 
that were in roughly Mendelian ratios. Genotyping of individual fish confirmed 
homozygote bcl6amdu21/mdu21 mutants were the smallest, with bcl6awt/mdu21 heterozygotes 
intermediate in size compared to wild-type bcl6awt/wt individuals (Figure 4.3A), which 
was exacerbated at 28 dpf (Figure 4.3B). Total length (Figure 4.3C), width (Figure 
4.3D) and eye diameter (Figure 4.3E) and ratio of length to eye diameter (Figure 4.3F) 
of individual genotyped fish was determined by imaging next to a ruler at 7 dpf, 14 dpf, 
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21 dpf and 28 dpf. Statistically significant decreases were observed in length, width and 
eye diameter in the bcl6awt/mdu21 and bcl6amdu21/mdu21 fish compared to their bcl6awt/wt 
siblings from 21 dpf, with homozygote mutants most markedly affected. The length/eye 
diameter ratio was also significantly decreased in bcl6amdu21/mdu21 zebrafish. 
Additionally, the bcl6amdu21/mdu21 mutants showed a clearly under-developed dorsal fin, 
abdominal fin, tail fin, swim bladder and eye, with the bcl6awt/mdu21 mutants showing an 
intermediate phenotype. 
4.3.3 Survival 
Relative survival of bcl6awt/wt (wt/wt) and bcl6amdu21/mdu21 (mdu21/mdu21) 
individuals was determined visually and expressed as a ratio of bcl6awt/mdu21 individuals 
genotyped at specific time points. It was noted that the proportion of smaller fish 
decreased over time, with none surviving to adulthood. Genotyping of adult fish 
confirmed that no bcl6amdu21/mdu21 fish were present (data not shown). Close analysis of 
the relative proportion of bcl6amdu21/mdu21 fish revealed that while present at an expected 
Mendelian ratio at 7 dpf, this genotype steadily decreased, with none observed at 60 
dpf (Figure 4.3G). The proportion of bcl6awt/mdu21 fish also increased to above the 




The findings presented in Chapter 3 indicated high conservation of BCL6A 
structure and regulation in zebrafish, suggesting conservation of function. Therefore, 
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the aim of Chapter 4 was to utilise zebrafish to further explore the role of vertebrate 
BCL6A. Genome editing was utilized to create a zebrafish bcl6a mutant that was 
analysed in detail. 
4.4.2 Generation of a zebrafish bcl6a mutant 
BCL6A is a multi-domain protein, with the N-terminal BTB/POZ domain 
important for protein-protein interaction and co-repressor complex formation (Brayer 
& Segal 2008; Lee & Maeda 2012). Analysis of zebrafish bcl6a gene identified a 
potential CRISPR target site in exon 3 that encodes the BTB/POZ domain. Zebrafish 
embryos were injected with CRISPR sg RNA and Cas9-encoding RNA, and a founder 
identified with a combined insertion/deletion (+59 bp/–28 bp) in this region. This allele 
(mdu21) introduces an in-frame stop codon that would truncate approximately 112 
amino acids of the BTB/POZ domain and all of the downstream PEST and zinc fingers 
domains suggesting it is likely a null allele. 
4.4.3 Role of bcl6a in development and growth 
In previous studies, Bcl6a knockout mice were shown to be visually 
indistinguishable from their wild-type littermates at birth (Cattoretti et al. 2005; Dent 
et al. 1997; Yoshida et al. 1999), with the mean body weights of Bcl6a knockout mice 
similar to wild-type until approximately three weeks of age (Yoshida et al. 1999). The 
bcl6amdu21/mdu21 zebrafish also displayed normal embryonic development and growth 
during the first two weeks after fertilization. Interestingly, a previous study using 
morpholino-mediated knockdown of zebrafish bcl6a showed colobomata (a retina 
defect) due to defective optic cup formation at 5 dpf (Lee, Lee & Gross 2013). However, 
no gross changes were observed in the eyes of bcl6amdu21/mdu21 mutant embryos. It is 
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possible that the retina defect observed may be due to the well-documented non-
specific effects of morpholinos (Bedell, Westcot & Ekker 2011).  
Bcl6a knockout mice were severely affected post-natally, with significantly 
decreased mean body weight compared to their wild-type littermates, while 
heterozygote mice were grossly normal (Dent et al. 1997; Yoshida et al. 1999). The 
bcl6amdu21/mdu21 mutants also displayed significant growth retardation in terms of total 
body length and width as well as eye diameter from 21 dpf. Interestingly, heterozygote 
bcl6awt/mdu21 juveniles showed an intermediate phenotype. Additionally, the 
bcl6amdu21/mdu21 and bcl6awt/mdu21 fish displayed undeveloped dorsal fin, abdominal fin, 
tail fin, swim bladder and eye. This indicates that bcl6a ablation results in overall 
growth and developmental retardation. 
 
4.4.4 Role of bcl6a in survival 
Loss of Bcl6a has been shown to severely affect survival. Bcl6a knockout mice 
showed signs of illness within 3 weeks of birth, including inflammation in the heart, 
lungs, spleen and liver (Dent et al. 1997; Mondal, Sawant & Dent 2010; Ye et al. 1997; 
Yoshida et al. 1999), which exacerbated with age. Most Bcl6a knockout mice died 
within 9 weeks of birth (Cattoretti et al. 2005; Dent et al. 1997; Yoshida et al. 1999). 
The survival of bcl6amdu21/mdu21 mutants was also significantly reduced from two weeks 
of age with none surviving at two months. In addition, the ratio of bcl6awt/wt to 
bcl6awt/mdu21 also continued to increase, indicating the heterozygote fish also had a 
survival defect. 
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4.4.5 Role of bcl6a in survival 
Loss of Bcl6a has been shown to severely affect survival. Bcl6a knockout mice 
showed signs of illness within 3 weeks of birth, including inflammation in the heart, 
lungs, spleen and liver (Dent et al. 1997; Mondal, Sawant & Dent 2010; Ye et al. 1997; 
Yoshida et al. 1999), which exacerbated with age. Most Bcl6a knockout mice died 
within 9 weeks of birth (Cattoretti et al. 2005; Dent et al. 1997; Yoshida et al. 1999). 
The survival of bcl6amdu21/mdu21 mutants was also significantly reduced from two weeks 
of age with none surviving at two months. In addition, the ratio of bcl6awt/wt to 
bcl6awt/mdu21 also continued to increase, indicating the heterozygote fish also had a 
survival defect. 
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4.4.6 Conclusion 
The findings of this Chapter suggest a conserved role of bcl6a in maintaining 
normal development, growth and survival in zebrafish. Lack of normal growth and 
development could be due to disruption of skeletal muscle differentiation, as suggested 
in other studies (Albagli-Curiel et al. 1998; Yoshida et al. 1999). On the other hand, it 
could relate to the immune system defects that might indirectly impact growth and 
development, and which likely is a key factor in the low survival rate observed, 
consistent with the severe and fatal outcomes of the inflammatory disorder observed in 
Bcl6a-deficient mice (Dent et al. 1997) .
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Figure 4.1 Targeting zebrafish bcl6a with CRISPR/Cas9. 
A. Schematic representation of zebrafish Bcl6a showing its constituent protein 
domains, including the targeted BTB/POZ domain (light green), PEST domain (orange) 
and ZF domain (dark green). The relative positions of intron/exon boundaries are 
indicated with vertical dotted lines and exon numbers, with the targeting site designated 
with an arrow. 
B. Schematic diagram of exons 2-5 of the zebrafish bcl6a gene including an expanded 
view of the sequence of exon 3 targeted by CRISPR/Cas9 with the gRNA sequence 
shown in red. 
C. Chromatogram and corresponding nucleotide and amino acid sequence obtained 
from homozygous bcl6awt/wt (wt/wt) and bcl6amdu21/mdu21 (mdu21/mdu21) individuals. 
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Figure 4.2 Analysis of zebrafish harbouring the bcl6amdu21 mutant allele during 
embryogenesis. 
A-E. Light microscopy of mixed progeny derived from bcl6awt/mdu21 in-crossing at 12 
hpf (A), 24 hpf (B), 48 hpf (C), 72 hpf (D) and of individually genotyped embryos at 7 
dpf (E). Representative images n>25 mixed progeny, repeated twice shown. 
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Figure 4.3 Analysis of zebrafish harbouring the bcl6amdu21 mutant allele post-
embryogenesis. 
A-B. Light microscopy of bcl6awt/wt (wt/wt), bcl6awt/mdu21 (wt/mdu21) and 
bcl6amdu21/mdu21 (mdu21/mdu21) progeny derived from bcl6awt/mdu21 in-crossing at 21 dpf 
(A) and 28 dpf (B) magnification power of 1x, 1.25x and 2x, respectively. 
Representative images n>25 mixed progeny followed by genotyping.  
C-F. Analysis of bcl6awt/wt (wt/wt), bcl6awt/mdu21 (wt/mdu21) and bcl6amdu21/mdu21 
(mdu21/mdu21) individuals for body length (H), body width (I), eye diameter (J) and 
the ratio of body length to eye diameter (K) at the indicated time-points. Shown is the 
mean ± SEM, with statistical significance indicated (***: p<0.001, **: p<0.01, *: 
p<0.05, ns: p˂0.05, n>25). 
G. Relative survival of bcl6awt/wt (wt/wt) and bcl6amdu21/mdu21 (mdu21/mdu21) 
individuals expressed as a ratio of bcl6awt/mdu21 individuals with the dotted line being 
the expected Mendelian ratio. Shown are values for groups of progeny (n=60) 
genotyped at the indicated time-points. 
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 Role of bcl6a in zebrafish haematopoiesis
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5.1 Introduction 
Previous studies have identified a pre-eminent role for BCL6A in germinal 
centre B cell formation (Phan & Dalla-Favera 2004), follicular helper T cell 
differentiation (Nurieva et al. 2009) and a range of other lymphoid functions such as in 
dendritic cells (Ohtsuka et al. 2011). It has also been implicated in macrophage activity, 
motility and morphology (Pixley et al. 2005; Yu et al. 2005).  
This Chapter aimed to explore the role of zebrafish bcl6a in embryonic 
haematopoiesis, with a focus on macrophages achieved by crossing the bcl6amdu21/mdu21 
allele onto the Tg(mpeg:GFP) background in which macrophages are fluorescently 
labelled. 
5.2 Analysis of immune cells in bcl6a mutants 
Embryonic lymphopoiesis was investigated by WISH analysis with the markers 
ikaros and rag1 at 3.5 and 5 dpf. Stained embryos were imaged and the area of 
expression determined with ImageJ. Homozygote bcl6amdu21/mdu21 embryos showed a 
significant decrease in expression of ikaros, a marker of T cell progenitors (Willett et 
al. 2001), compared to bcl6awt/wt siblings at 5 dpf, but no difference was apparent 
between bcl6awt/mdu21 and bcl6awt/wt embryos (Figure 5.1A-B). Expression of rag1, a 
marker of mature T cells (Feng et al. 2005) was significantly decreased in both 
bcl6awt/mdu21 and bcl6amdu21/mdu21 embryos compared to bcl6awt/wt siblings at both 3.5 and 
5 dpf, but to a much greater extent in bcl6amdu21/mdu21 embryos (Figure 5.1C-D). 
Myelopoiesis was investigated by examining expression of l-plastin and mpo at 
5 dpf by using WISH, with the number of positive cells manually counted. The number 
Chapter 5 
  78 
of cells expressing l-plastin, a marker of leukocytes including macrophages (Bennett et 
al. 2001), was significantly decreased in bcl6awt/mdu21 and bcl6amdu21/mdu21 embryos at 5 
dpf compared to bcl6awt/wt embryos but again bcl6amdu21/mdu21 embryos were 
significantly reduced compared to heterozygotes (Figure 5.2A). In contrast, no 
significant difference in the number of cells expressing mpo, a marker of granulocytes 
(Shen et al. 2013), was observed in bcl6awt/mdu21 and bcl6amdu21/mdu21 embryos compared 
to bcl6awt/wt at 5 dpf (Figure 5.2B). 
5.3 Response of bcl6a mutants to bacterial infection 
The bcl6a mutants were next investigated in a bacterial infection assay. The 
progeny bcl6awt/mdu21 in-crosses were subjected to injection of GFP+ E. coli at 4 dpf. 
Surviving embryos were imaged by fluorescent microscopy until 24 hour post infection 
(hpi) and subsequently genotyped, with the fluorescence intensity used to indicate the 
bacterial load. The bcl6awt/wt, bcl6awt/mdu21 and bcl6amdu21/mdu21 embryos showed no 
difference in fluorescence at 0.5 hpi. At 12 and 18 hpi the fluorescence intensity was 
increased in bcl6amdu21/mdu21 compared to bcl6awt/wt and bcl6awt/mdu21 embryos. No 
bcl6amdu21/mdu21 were detected at 24 hpi, while no differences were observed between 
bcl6awt/wt and bcl6awt/mdu21 embryos (Figure 5.3A-B). No mortality was observed in the 
injected embryos at 0.5 hpi, but from 12 hpi decreased survival of bcl6amdu21/mdu21 was 
observed, reaching zero survival at 24 hpi, while bcl6awt/wt and bcl6awt/mdu21 showed 
similar high survival rate (Figure 5.3C). 
5.4 Response of bcl6a mutants to wounding 
To further understand the effect of bcl6a ablation on macrophages, a wound-
healing assay was performed. To facilitate this, the bcl6amdu21 allele was crossed onto 
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the Tg(mpeg1:GFP) background, in which macrophages are marked with GFP 
(Wittamer et al. 2011). Tg(mpeg1:GFP) bcl6awt/mdu21 fish were incrossed to generate 
wild-type, heterozygote and homozygote bcl6a mutants on the Tg(mpeg1:GFP) 
transgenic background, which were visualised by fluorescence microscopy. At 4 dpf 
embryos were subjected to wounding by tail fin transection (Feng et al. 2010) and 
imaged at various times post wounding, after which individual embryos were 
genotyped. A significant decrease in total GFP+ cells number was seen in 
bcl6amdu21/mdu21 compared to the bcl6awt/wt embryos but no significant difference in total 
cell number was observed in bcl6awt/mdu21 embryos. Analysis of bcl6awt/wt embryos 
indicated that GFP+ cells peaked in the wound at 4 hours post wounding (hpw) before 
decreasing at later time points (Figure 5.4A-C). In bcl6awt/mdu21 embryos, GFP+ cells 
peaked at 8 hpw, whereas bcl6amdu21/mdu21 embryos showed both delayed migration 
kinetics and reduced numbers of GFP+ cells (Figure 5.4A-C). 
To gain a greater understanding of macrophage motility rate, the experiment 
was repeated but embryos were visualised by fluorescence microscopy from 0.5 hpw 
at 15 min intervals until the first GFP+ cell reached the wound site, after which embryos 
were genotyped. In both bcl6awt/wt and bcl6awt/mdu21 embryos, the first GFP+ cell reached 
the wounding site between 0.75-1.0 hpw, while in bcl6amdu21/mdu21 embryos this was 
extended to 3.25-3.5 hpw (Figure 5.4D-E). 
5.5 Discussion 
5.5.1 Overview 
BCL6A has been shown to be a master regulator of B and T cell differentiation 
(Bassil et al. 2014; Nurieva et al. 2009), and also plays an essential role in macrophage 
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function (Mondal, Sawant & Dent 2010; Pixley et al. 2005; Toney et al. 2000). This 
Chapter aimed to understand the effect of bcl6a on early lymphopoiesis and 
myelopoiesis, including analysis of macrophage function. 
5.5.2 Role of bcl6a in lymphopoiesis 
Lymphopoiesis is severely affected in Bcl6a knockout mice, which exhibit a 
significant reduction in pre-B cell self-renewal and differentiation in the bone marrow 
(Duy et al. 2010) and failure of B cell germinal centre formation (Cattoretti et al. 2005; 
Huang et al. 2014). On other hand, T cell subsets were variably affected in the Bcl6a 
knockout mice: T helper 1 (Th1), T helper 2 (Th2) and T helper 17 (Th17) were 
dramatically increased whereas there was a significant decrease in the survival and 
differentiation of follicular T helper (Tfh) cells (Dent et al. 1997; Hollister et al. 2013; 
Mondal, Sawant & Dent 2010; Nance et al. 2015; Nurieva et al. 2009). As in mammals, 
zebrafish possesses both T and B cells (Hansen & Zapata 1998; Langenau & Zon 2005; 
Trede & Zon 1998). T cells precursors arise at 24-30 hpf in the definitive wave of 
haematopoiesis in zebrafish and, as in mammals, multiple T cell classes are produced 
and mature in the thymus (Bertrand et al. 2007; Haire et al. 2000; Seelye et al. 2016). 
In this Chapter, the bcl6amdu21/mdu21 mutants displayed a significant decrease in 
lymphocyte populations during embryogenesis including precursor (ikaros+) and 
mature (rag1+) T lymphocyte populations. This finding suggests an essential role of 
bcl6a in the survival and/or differentiation of early T cells in zebrafish. It was difficult 
to study B cells since there arise three weeks post fertilisation (Danilova et al. 2000) 
when survival of bcl6amdu21/mdu21 embryos was already compromised. 
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5.5.3 Role of bcl6a in myelopoiesis 
BCL6A has been previously implicated in the development of myeloid cells, 
monocytes and dendritic cells (Pantano et al. 2006; Yamochi et al. 1997; Zhang et al. 
2014). The significantly reduced number l-plastin expressing cells and GFP+ cells in 
Tg(mpeg.GFP) fish indicated a reduction in macrophages in the bcl6amdu21/mdu21 
embryos. 
5.5.4 Role of bcl6a in macrophage function 
Bcl6a-/- mice showed dysregulation in chemokines gene expression in 
macrophages (Toney et al. 2000). In addition, Bcl6a-/- bone marrow-derived 
macrophages exhibited alterations in their morphology and motility (Pixley et al. 2005). 
The macrophages in bcl6amdu21/mdu21 embryos displayed significantly decreased motility 
in response to wounding. This finding may result from dysregulated expression of 
chemokines and cytokines due to ablation of bcl6a as detailed in Bcl6a-/- mice (Mondal, 
Sawant & Dent 2010; Pixley et al. 2005; Toney et al. 2000). 
5.5.5 Role of bcl6a in the response to infection 
The bcl6amdu21/mdu21 mutants were also found to be less to able to control 
bacterial infection. Following injection of GFP+ E. coli, these mutants exhibited 
enhanced bacterial load after 12 hpi and reduced survival. Whether this was due to the 
effects on macrophage function and/or reduced number of early T cells remains to be 
determined. 
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5.5.6 Conclusion 
The findings in this Chapter identify a role for zebrafish bcl6a in the 
development of early lymphoid and myeloid cells. They also suggest bcl6a participates 
in the regulation of macrophage function. These immune system defects in the bcl6a 
knockouts likely contribute to the poor survival of the bcl6a mutant fish, including in 
response to bacterial infection. 
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Figure 5.1 Analysis of lymphoid cells in bcl6a mutant zebrafish. 
A-D. Whole-mount in situ hybridization of bcl6awt/wt, bcl6awt/mdu21 and bcl6amdu21/mdu21 
embryos with ikaros at 3.5 dpf (A) and 5 dpf (B) and rag1 at 3.5 dpf (C) and 5 dpf (D). 
Representative images are shown along with the expression area (μm2) quantified for 
each group, showing values for individual embryos, as well as mean ± SEM. (*: p<0.05; 
***: p<0.001; ns: not significant, n>25 mixed progeny, repeated twice).
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Figure 5.2 Analysis of myeloid cells in bcl6a mutant zebrafish. 
A-B. Whole-mount in situ hybridization of bcl6awt/wt, bcl6awt/mdu21 and bcl6amdu21/mdu21 
embryos with l-plastin at 5 dpf (A) and mpo at 5 dpf (B). Representative image are 
shown along with the number of cells quantified for each group, showing values for 
individual embryos as well as mean ± SEM.  (*: p<0.05; **: p<0.01; ***: p<0.001; ns: 
not significant, n>25, repeated mixed progeny). 
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Figure 5.3 Analysis of bacterial infection in bcl6a mutant zebrafish. 
A-C. Infection of 4 dpf embryos with GFP+ E.coli showing representative bcl6awt/wt 
(wt/wt), bcl6awt/mdu21 (wt/mdu21) and bcl6amdu21/mdu21 (mdu21/mdu21) embryos at 0.5, 12 
and 18 hpi following fluorescence microscopy and imaging (n>60 mixed progeny of each 
time point, repeated twice) (A). Bacterial load intensity was assessed on a 5 point scale 
(0-4) for bcl6awt/wt (wt/wt), bcl6awt/mdu21 (wt/mdu21) and bcl6amdu21/mdu21 (mdu21/mdu21) 
embryos at 0.5, 12, 18 and 24 hpi showing mean ± SEM (*: p<0.05; ns: not significant). 
(B). The survival rate for bcl6awt/wt (wt/wt), bcl6awt/mdu21 (wt/mdu21) and bcl6amdu21/mdu21 
(mdu21/mdu21) embryos at 0.5, 12, 18 and 24 hpi (C).
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Figure 5.4 Analysis of macrophage migration in response to injury in bcl6a mutant 
zebrafish. 
A. Relative number of GFP+ cells of bcl6awt/wt (wt/wt), bcl6awt/mdu21 (wt/mdu21) and 
bcl6amdu21/mdu21 (mdu21/mdu21) embryos on Tg(mpeg.GFP) background, as determined 
by retrospective genotyping, at 4 dpf, showing values for individual embryos, as well 
as mean ± SEM. (***: p<0.001; ns: not significant, n=30). 
B-C. Wound healing assay on 4 dpf embryos subjected to injury via tail fin transection 
Shown are fluorescence images of representative bcl6awt/wt (wt/wt), bcl6awt/mdu21 
(wt/mdu21) and bcl6amdu21/mdu21 (mdu21/mdu21) embryos on Tg(mpeg.GFP) 
background, as determined by retrospective genotyping, at 0 hpw, 4 hpw, 8 hpw and 
24 hpw as indicated (B). The sites of tail fin transection are indicated with the dotted 
lines. Quantitation of the total number of GFP+ macrophage migrated at the indicated 
timepoint, showing values for individual embryos, as well as mean ± SEM.  (*: p<0.05; 
**: p<0.01; ***: p<0.001; ns: not significant, n>20 mixed progeny) (C). 
D-E. Wound healing assay as described above, except embryos were imaged from 0.5 
hpw every 15 min. Shown are fluorescence images from representative bcl6awt/wt 
(wt/wt), bcl6awt/mdu21 (wt/mdu21) and bcl6amdu21/mdu21 (mdu21/mdu21) embryos (n>25 
mixed progeny) as determined by retrospective genotyping, at the times indicated (D). 
Relative frequency distribution of embryos of the indicated genotypes by the time at 
which the first GFP+ cell was observed to have migrated to the cut site (E). 
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6.1 General discussion 
6.1.1 Overview 
BCL6A is a transcriptional repressor, consisting of a BTB/POZ domain 
responsible for recruiting co-repressors, a PEST domain controlling protein stability, 
and a six zinc finger DNA binding domain (Basso & Dalla-Favera 2010). BCL6A was 
first identified as a target gene for chromosomal translocations in non-Hodgkin’s 
lymphomas (Ye et al. 1993b). Several of these resulted in disruption of a region of the 
BCL6A promoter containing tandem STAT5 binding sites, implicating STAT5 as an 
important negative regulator (Kikuchi et al. 2000; Walker, Nelson & Frank 2007). The 
target sites for BCL6A also overlap with those for STAT5 providing a mechanism by 
which BCL6A can also negatively regulate a subset of STAT5 target genes (Walker, 
Nelson & Frank 2007). BCL6A has been shown to play important roles in the 
development and function of lymphoid and myeloid cells (Basso et al. 2010), with 
additional roles in non-haematopoietic cells (Bajalica-Lagercrantz et al. 1998). 
This thesis aimed to further our understanding of BCL6A, its evolution, 
expression, regulation and function. Chapter 3 examined the conservation of BCL6A-
related genes in zebrafish and characterised the embryonic expression of the zebrafish 
bcl6a gene and its regulation by STAT5 homologues. Chapter 4 described the 
generation of a bcl6a knockout allele, and investigated the impact of bcl6a ablation on 
zebrafish development, growth and survival. Chapter 5 further explored the effects of 
bcl6a mutation on immune cell development and function. 
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6.1.2 BCL6 family evolution 
Mammals have two BCL6 proteins, BCL6A and BCL6B, which display 65%, 
100% and 94% identity across the BTB/POZ, PEST and zinc finger domains, 
respectively (Okabe et al. 1998). Invertebrates possess a single BCL6-related protein, 
typified by Ken & Barbie (Ken) found in fruit-fly. This contains a BTB/POZ domain 
and a zinc finger domain containing three fingers (Kuhnlein, Chen & Schuh 1998) with 
57% and 55% identity, respectively, to human BCL6A, but no PEST domain 
(Lukacsovich et al. 2003). 
Chapter 3 identified zebrafish orthologues to the mammalian BCL6A and 
BCL6B genes, termed bcl6a and bcl6b, as well as an additional fish-specific gene, 
bcl6ab. This suggests an evolutionary model in which a primordial ken/BCL6 
homologue existed in the common ancestor of invertebrates and vertebrates, which 
evolved into a precursor of the ken-related genes in extant invertebrates and a BCL6A/B-
precursor in early vertebrates (Figure 6.1). The latter subsequently duplicated prior to 
the divergence of bony and cartilaginous fish to yield distinct BCL6A and BCL6B 
precursors that ultimately gave rise to the present-day mammalian genes. A subsequent 
teleost fish-specific duplication yielded an additional bcl6ab gene, most probably 
derived from the bcl6a lineage, along with retention of both bcl6a and bcl6b. It is likely 
that the respective duplications were mediated by the whole genome duplication 
(WGD) events that have occurred during vertebrate evolution (Reams & Roth 2015), 
with the initial duplication to yield BCL6A and BCL6B precursors occurring as part of 
either the WGD1 or WGD2 that transpired during early vertebrate evolution, with the 
additional duplication that generated bcl6ab occurring through the teleost fish-specific 
WGD3 event. 
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6.1.3 Expression of bcl6a 
BCL6A has a complex expression pattern throughout the lifespan, with both 
haematopoietic and non-haematopoietic expression, the latter notably including 
neurosensory tissues. With respect to mammalian development, high expression of 
BCL6A was observed in thymocytes from human foetal samples at 21 weeks gestation 
(Hyjek et al. 2001), and for Bcl6a in the foetal mouse thymus at 17 days gestation 
(Bajalica-Lagercrantz et al. 1998). Chapter 3 demonstrated that bcl6a was similarly 
highly expressed in the developing thymus during zebrafish embryogenesis, suggesting 
a conserved role in early T lymphocyte development across vertebrates. The bcl6a gene 
was also expressed earlier in the zebrafish ALM and PLM, indicative of a potential role 
in the development of other haematopoietic lineages as well. 
With respect to developing neuro-sensory tissue, Bcl6a expression has been 
reported in the olfactory epithelium of prenatal mice (Bajalica-Lagercrantz et al. 1998). 
Zebrafish bcl6a expression has also been previously reported in the embryonic retina 
(Lee, Lee & Gross 2013), which was confirmed in Chapter 3 along with additional 
expression in the developing brain. This is consistent with expression of fruit-fly ken at 
the onset of gastrulation in the cephalic furrow and later in the larval eye-antenna 
(Arbouzova, Bach & Zeidler 2006). Bcl6a expression was additionally present in pre-
natal mouse skeletal muscle, esophagus, upper airway lining and skin (Bajalica-
Lagercrantz et al. 1998). Chapter 3 identified strong expression of bcl6a in early 
zebrafish skeletal muscle precursors (somites), while ken was also expressed at the 
onset of gastrulation in the gut (Arbouzova, Bach & Zeidler 2006). Collectively, this 
may suggests a conserved broader role for ken/BCL6 genes in non-haematopoietic 
tissues. 
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In the adult, expression of BCL6A was identified in peripheral blood leukocytes 
and lymph nodes in humans (Bajalica-Lagercrantz et al. 1997), and of Bcl6a in the adult 
mouse thymus (Bajalica-Lagercrantz et al. 1998). High expression of BCL6A has also 
been observed in pre-B and mature B cells lines with lower expression in T cell, 
myeloid and erythrocyte lines derived from both humans and mice (Allman et al. 1996). 
This thesis did not investigate expression of bcl6a in adult zebrafish. However, the 
pufferfish bcl6a homologue was expressed in adult thymus and kidney, the teleost bone 
marrow equivalent (Ohtani, Miyadai & Hiroishi 2006). Collectively, this indicates 
potential conserved roles for BCL6A in adult blood and immune cells. 
It been shown that the BTB domain in Ken is important in the neural 
development in fruit-fly (Badenhorst, Finch & Travers 2002). BCL6A expression has 
also been described in adult human spinal cord (Bajalica-Lagercrantz et al. 1997), with 
Bcl6a shown to be expressed in the adult mouse cerebral cortex (Bajalica-Lagercrantz 
et al. 1998) and bcl6a in the adult pufferfish brain and nasal cavity (Ohtani, Miyadai & 
Hiroishi 2006). Human BCL6A was also expressed in adult skeletal muscle, thyroid, 
trachea, ovary and prostate (Bajalica-Lagercrantz et al. 1997), with mouse Bcl6a 
expressed in skeletal muscle (Albagli-Curiel et al. 1998) and pufferfish bcl6a in skeletal 
muscle, intestine and ovary (Ohtani, Miyadai & Hiroishi 2006). This highlights likely 
conservation across vertebrate species within neuro-sensory and other tissues. 
6.1.4 Stat5-mediated regulation of bcl6a 
BCL6A expression is negatively regulated by STAT5, with STAT5 able to 
directly repress BCL6A transcription through binding to tetrameric binding sites in the 
BCL6A promoter that overlap with the first exon of the gene (Kikuchi et al. 2000; 
Walker, Nelson & Frank 2007). In lymphoid cells, this repression principally occurs in 
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response to specific cytokines, including both interleukin 2 (IL-2) and interleukin 21 
(IL-21) that strongly activate STAT5 via receptor complexes using the IL-2 receptor 
common γ chain (IL-2Rγc) (Eto et al. 2011; Vogelzang et al. 2008; Walker, Nelson & 
Frank 2007). Deletion of these STAT5 binding sites results in high BCL6A expression 
that directly contributes to lymphoma development (Walker, Nelson & Frank 2007). 
Chapter 3 demonstrated almost complete conservation of the tandem tetrameric STAT5 
binding sites within the zebrafish bcl6a promoter, which could exert a repressive 
function in vitro. In addition, ablation of stat5.2, and to a lesser extent stat5.1, increased 
bcl6a expression. Fruit-fly ken has been also demonstrated to be a Stat92e target gene 
in both the eye imaginal disc (Flaherty et al. 2009) and border cells of the ovary (Yoon, 
Meinhardt & Montell 2011). This suggests a highly conserved mode of reciprocal gene 
regulation that may contribute to repression of BCL6A-related genes in both lymphoid 
and non-lymphoid cell types. Analysis of the evolution of BCL6A and STAT5 genes 
indicates that this regulation presumably originated prior to the last common ancestor 
of vertebrates and invertebrates, and was retained in the STAT5/BCL6A axis that 
emerged after WGD2 (Figure 6.1). 
6.1.5 Role of bcl6a in haematopoietic cells 
BCL6A is well known as a master regulator of GC B cells where it is required 
for maintaining DNA integrity during differentiation (Basso & Dalla-Favera 2010; 
Phan & Dalla-Favera 2004). However, BCL6A also influences other haematopoietic 
cell populations. High expression of Bcl6a is observed in the pre-natal thymus and 
spleen (Bajalica-Lagercrantz et al. 1998), underpinning the role of BCL6A in the 
regulation of Th cell subset lineage differentiation (Hatzi et al. 2015; Nurieva et al. 
2009). Thus, Bcl6a knockout mice displaying increased differentiation of Th2 and Th17 
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T cells (Mondal, Sawant & Dent 2010), but decreased Tfh cells (Hatzi et al. 2015), with 
conditional deletion of Bcl6a in T cells leading to a 90% decrease in Tfh cells. 
Moreover, IgG antigen was 5 fold lower than that in the wild-type, which showed the 
importance of BCL6A in the Tfh survival (Hollister et al. 2013). Bcl6a knockdown in 
naive CD4+ T cells also resulted in increased Th9 differentiation (Bassil et al. 2014). 
The findings in Chapter 5 revealed a significant decrease in lymphoid precursors and 
early T lymphocytes in bcl6a-deficient zebrafish embryos. Due to the lack of 
availability of antibodies or other markers for zebrafish T cell subsets, it remains 
unclear exactly which of these is affected in the bcl6a knockout fish. However, it is 
clear that BCL6A plays a conserved role in T cell biology overall. 
Bcl6a knockout mice also fail to form GC B cells with the production of high 
affinity antibodies severely ablated (Basso & Dalla-Favera 2010, 2012; Dent et al. 
1997; Huang, Hatzi & Melnick 2013). B cells first appear around 21 dpf in zebrafish, 
where the survival of bcl6a mutants was already severely compromised, thereby 
precluding their effective study. Moreover, there is currently a lack of suitable reagents 
to identify all relevant T or B cell subsets in zebrafish.  
Another target of BCL6A regulation are the macrophages. Macrophages are 
essential for innate immunity in response to pathogens, foreign bodies and injury, 
mediating inflammatory response through production of chemokines, which provoke 
responses from T cells subsets (particularly Th2 cells) (Crapster-Pregont et al. 2012). 
Inactivation of Bcl6a in bone-marrow derived macrophages resulted in significantly 
decreased macrophage motility, polarization and spreading (Pixley et al. 2005). 
Additionally, LPS injection of adult Bcl6a-/- mice resulted in increased MCP-1, MCP3 
and MRP-1 chemokine secretion by macrophages compared to their wild-type 
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littermates, which underlines the severe Th2 inflammation in the Bcl6a-/- mice (Toney 
et al. 2000). Interestingly, none of the previous studies of Bcl6a knockout mice have 
investigated the relative number of macrophages. Significant decreased quantity and 
motility of macrophages were observed in bcl6amdu21/mdu21 embryos. Of note, a fruit-fly 
hemocytes, which represent innate immune cells, were sensitive the effects of Ken, 
which could repress JAK-STAT pathway signalling in these cells (Arbouzova, Bach & 
Zeidler 2006). This suggest a conserved role in innate immunity. 
Finally, the effects of bcl6a ablation on T cells and macrophages may explain 
the enhanced susceptibility of bcl6amdu21/mdu21 embryos to bacterial infection. 
6.1.6 Role of bcl6a in non-haematopoietic cells 
Fruit-fly Ken has been found to contribute to the differentiation of 
photoreceptor (neuronal) cells and cone (non-neuronal) cells during eye development 
(Wen et al. 2000). A previous study showed that bcl6a knockdown in zebrafish embryos 
resulted in malformation of the optic cup during embryogenesis (Lee, Lee & Gross 
2013). Chapter 3 confirmed strong expression of bcl6a in the developing zebrafish eye 
but no overt eye defects were observed in bcl6amdu21/mdu21 mutants in Chapter 4, while 
none have been reported in Bcl6a mutant mice. More work is required to understand 
the discrepancies, especially between the zebrafish studies. 
Previous studies on neonatal mice showed that Bcl6a is essential in the terminal 
phase of keratinocytes (Yoshida et al. 1996), olfactory epithelium, skeletal muscles, 
upper airways epithelium and esophagous (Bajalica-Lagercrantz et al. 1998). Bcl6a 
knockout mice displayed growth retardation and died within 5 weeks after birth with 
strong Bcl6a expression observed during skeletal muscle differentiation suggesting a 
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potential role in growth (Albagli-Curiel et al. 1998; Yoshida et al. 1999). Consistent 
with this, significant growth retardation was observed in bcl6amdu21/mdu21 fish from 21 
dpf suggesting this might be a common phenotype across vertebrates. However, the 
bcl6amdu21/mdu21 also displayed a thinner body, which may be due to a direct effect on 
adipose tissue, as murine Bcl6a knockouts have been shown to possess disrupted lipid 
metabolism (LaPensee et al. 2014). The bcl6amdu21/mdu21 fish also displayed reduced 
survival. A similar phenotype is observed in the Bcl6a knockout mice have also been 
connected with the immune system perturbations, with these mice showing excessive 
inflammatory responses due to B cell germinal centre formation failure and production 
of low affinity antibodies (Fukuda et al. 1997; Huang et al. 2014; Ye et al. 1997), 
leading to profound myocarditis and vasculitis (Dent et al. 1997). This could also 
impact on growth indirectly. 
Bcl6a knockout mice showed 80% lower spermatozoa than wild-type 
littermates at 8 weeks of age, with only 15% of the Bcl6a knockout mice being fertile 
due to high rates of apoptosis in spermatocytes (Kojima et al. 2001). Ken has also been 
shown to maintain self-renewal capacity of testis cells (Issigonis & Matunis 2012), 
proper terminalia development (Lukacsovich et al. 2003), behavioural responses to 
visual stimuli, including escape behaviour and synaptic function (Allen et al. 2007). In 
this thesis, due to lethality of the bcl6a knockout it was not possible to investigate the 
role of bcl6a in these adult phenotypes. 
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6.2 Future directions 
6.2.1 Overview 
The results of this thesis have provided some clear insights into the evolution, 
regulation and function of zebrafish bcl6a. However, there remain several areas for 
further exploration with respect to bcl6a and related genes (Table 6.1), some of which 
are articulated below. 
6.2.2 Bcl6a-mediated gene regulation 
Underpinning the role of mammalian BCL6A in the development and function 
of a variety of haematopoietic and non-haematopoietic cells is its strong repressive 
function, which is yet to be explored in zebrafish.  However, the BTB/POZ domain was 
found to be essential for Bcl6a transcriptional co-repressor recruitment in the torafugu. 
(Okabe et al. 1998). This domain is well conserved in zebrafish, suggesting the 
zebrafish Bcl6a has the same repressive properties. 
6.2.2.1  Genes regulated by Bcl6a 
BCL6A has been shown to negatively regulate a wide range of genes 
responsible for DNA integrity (Phan & Dalla-Favera 2004; Ranuncolo, Polo & Melnick 
2008), cell cycle checkpoints (Ranuncolo, Polo & Melnick 2008) and apoptosis (Baron 
et al. 2002). It would be of great interest to examine if similar genes were regulated by 
zebrafish Bcl6a using Next Gen Sequencing (NGS) approache (Gebauer et al. 2015). 
Due to the survival defects observed in bcl6amdu21/mdu21 fish, this would necessarily be 
performed on individual embryos from a bcl6a+/mdu21 in-cross with samples processed 
for both NGS and genotyping. Given the high conservation of the zinc finger domains, 
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it is anticipated that the DNA target sequences would be conserved between zebrafish 
Bcl6a and mammalian BCL6A, providing a means to identify potential direct Bcl6a 
targets. Tissue-specificity of such genes could be determined by isolating specific cell 
populations, such as early macrophages using the Tg(mpeg:GFP) line (Iqbal et al. 
2014), and comparing expression between those obtained from wild-type and mutant 
embryos. 
6.2.2.2  Role in regulating STAT5-responsive genes 
BCL6A-related proteins have been demonstrated to negatively regulate 
transcription of a subset of STAT5-responsive genes mediated via overlapping target 
sequences. For example, mammalian BCL6A was shown to downregulate specific 
target genes that are upregulated by STAT5, including those encoding β-casein (CSN2) 
macrophage inflammatory protein 1-α (MIP1α), cytokine-induced Src homology 2-
domain containing protein (CISH) and insulin-like growth factor-1 (IGF1) (Chen et al. 
2009; Eleswarapu, Gu & Jiang 2008; Happ & Groner 1993; Logarajah et al. 2003; 
Shaffer et al. 2000; Socolovsky et al. 1999). This findings correlate with the reciprocal 
regulation of growth hormone target genes (Lin et al. 2014), thus Bcl6a knockout lead 
to increased Socs2 expression (Chen et al. 2009). In fruit-fly, Ken has also been shown 
to repress a subset of Stat92E targets (Arbouzova, Bach & Zeidler 2006; Kwon et al. 
2008), with this regulatory interaction shown to be functionally important genetically. 
Thus, loss of one copy of ken was able to enhance the overgrowth of adult eye caused 
by misexpression of the JAK-STAT pathway ligand-encoding upd (Bach et al. 2003), 
while enhancement of ken allele strength decreased wing vein defects associated with 
the stat92E allele (Yan et al. 1996). The role of Bcl6a in regulating Stat5-responsive 
genes in zebrafish could be achieved by using the NGS data that would result from the 
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studies described in Section 6.2.2.1 and comparing this with the data already available 
in the laboratory relating to Stat5.1 and Stat5.2 target genes. Inversely co-regulated 
targets with overlapping Bcl6a and Stat5 binding sites in their promoters would be 
prime candidates for further study. 
6.2.3 Role of bcl6a in juvenile and adult zebrafish 
6.2.3.1 Approaches to the study of later time points 
This thesis identified a role for bcl6a in embryonic haematopoiesis and 
immunity as well as juvenile growth and survival. However, the lethality observed 
meant that the effects of bcl6a ablation on juvenile and adult fish could not be examined 
in detail. Maintenance of Bcl6a-/- mice in a pathogen free environment allowed them to 
survive to 8 and 12 weeks of age, which allowed the effects of Bcl6a ablation on 
spermatogenesis to be determined (Kojima et al. 2001). Pathogen-free conditions have 
been successfully used to raise immunodeficient zebrafish (Jung et al. 2016), which 
would be worth exploring for bcl6a mutants to facilitate study at later timepoints. 
Alternatively, specific BTB/POZ domain mutants were found to ablate the abnormal 
inflammatory responses observed in complete Bcl6a mouse knockouts, allowing the 
impacts on germinal centre B cells to be studied without this complication (Huang, 
Hatzi & Melnick 2013). A similar zebrafish bcl6a mutant might also provide useful 
additional insights. Use of conditional or inducible bcl6a mutants (Hollister et al. 2013) 
could also facilitate studies at later developmental stages and into adulthood. 
6.2.3.2 Key areas to investigate 
The ability to study bcl6a-deficient fish at later time points would facilitate a 
range of studies. It would allow further investigation into the significant retardation in 
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growth and survival in juvenile bcl6amdu21/mdu21 zebrafish. For example, investigating 
whether the effect on growth was direct, potentially through effects on growth hormone 
signalling, or whether the growth and/or survival effects were indirect, being a 
secondary impact of either having insufficient lymphocytes and (functional) 
macrophages resulting in immunodeficiency or, alternatively, a hyper-inflammatory 
response caused by dysfunction macrophages, as described in mice (Toney et al. 2000). 
Analysis of expression of key growth hormone-regulated genes, such as IGF1, would 
be valuable in exploring causes for the growth defect, as would characterisation of a 
specific BTB/POZ domain mutant that might specifically ablate the inflammatory 
response. Augmenting survival of bcl6a-ablated zebrafish would also facilitate the 
study of B cells, which do not emerge in zebrafish until after week 3 of development 
(Page et al. 2013), while also allowing the study of T cells, NK cells and macrophages 
in juveniles and in adults. However, a key challenge that remains is how to identify the 
relevant sub-populations that are perturbed in Bcl6a-deficient mice, such as GC B cells 
and Tfh (Bajalica-Lagercrantz et al. 1997; Hollister et al. 2013; Nance et al. 2015; 
Nurieva et al. 2009), since the understanding of lymphoid cell subsets in zebrafish 
remains relatively rudimentary. Finally, surviving bcl6a mutants would additionally 
allow the investigation of relevant non-haematopoietic functions, such as behavioural 
responses (Allen et al. 2007), locomotor activity (Jordan et al. 2007), as well as stem 
cell renewal in the testes (Issigonis & Matunis 2012) and brain (Berger et al. 2012). In 
each case NGS approaches could add an invaluable transcriptional perspective. 
6.2.4 Role of bcl6a in oncogenesis  
BCL6A was first identified in DLBCL (Ye et al. 1993a), with BCL6A found to 
be highly expressed in many lymphomas, including DLBCL and FL (Green et al. 2014; 
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Wagner, Ahearne & Ko Ferrigno 2011). This thesis did not investigate the role of bcl6a 
in oncogenesis in zebrafish. However, the work presented confirmed that zebrafish 
bcl6a shows high conservation in terms of sequence, regulation and function to its 
mammalian counterparts. Therefore, it is expected that bcl6a would have potential to 
exert a similar oncogenic effect as human BCL6A. To recapitulate the human clinical 
situation, bcl6a could be specifically over-expressed in lymphoid populations (Bassil 
et al. 2014; Mondal, Sawant & Dent 2010), using promoters such as rag1 for T 
lymphocytes (Collins et al. 1996) and igm for B lymphocytes (Toyama et al. 2002). 
Alternatively, the highly conserved, repressive tetrameric STAT5 sites identified in the 
bcl6a promoter could be deleted using appropriate genome editing strategies to 
indirectly mediate increased bcl6a expression as seen in clinical samples (Walker, 
Nelson & Frank 2007). This would provide an opportunity to create the first zebrafish 
models of DLBCL and FL, as well as investigate unexplored aspects of zebrafish 
immunology. 
6.2.5 Role of bcl6a-related genes 
While knowledge of BCL6A is steadily increasing, understanding of BCL6B 
remains more limited. BCL6B shows high identity to BCL6A and binds to comparable 
DNA sequences, with similar targets for transcriptional repression (Hartatik et al. 2001; 
Okabe et al. 1998; Takenaga et al. 2003). Bcl6b knockout mice exhibited an 
haematopoietic stem cells (HSCs) defect, with deficits in CD8+ and memory T cells as 
well as neutrophils, but elevated erythrocytes and monocytes, yet remain viable and 
fertile (Broxmeyer et al. 2007; Manders et al. 2005). BCL6B has also been implicated 
as a tumour suppressor, with BCL6B expression decreased in a variety of tumours, such 
as colorectal cancer (Hu et al. 2015), gastric cancer (Deng et al. 2014), chronic 
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lymphocytic leukaemia (Greipp et al. 2013) and hepatocellular carcinoma (Wang et al. 
2014). 
The function of the fish-specific bcl6ab gene remains completely unknown. 
Many genes in teleosts consist of two paralogues that have resulted from the teleost-
specific WGD3 event (Nakao et al. 2006; Taylor et al. 2001). Such duplicated genes 
can follow several different trajectories. Mostly one of the gene duplicates becomes 
non-functional and is lost. However, when retained the additional genes typically gain 
new functions (neofunctionalization), partition the functions of the ancestral gene 
(subfunctionalization) or a combination of both (He & Zhang 2005; Lynch & Force 
2000). In zebrafish, WGD3-mediated gene duplicates have typically been shown to 
display subfunctionalization in comparison to their human orthologues (Cresko et al. 
2003; Force et al. 1999; Kassahn et al. 2009). 
Zebrafish provides an attractive platform to investigate the role of both bcl6b 
and bcl6ab through the generation of mutants in a similar manner as was performed for 
bcl6a. Crossing of these mutants also provides opportunities for examining functional 
overlap and redundancy between the bcl6a-related genes. Next Gen sequencing 
strategies could then provide the possibility of relating this back to unique and 
combinatorial regulation of specific target genes.  
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Figure 6.1 Evolution of BCL6 and STAT5 genes. 
Schematic diagram showing the evolution of BCL6 and STAT5 genes, highlighting 
relevant genes from invertebrates (fruit-fly, brown), mammals (human, orange) and 
teleost fish (zebrafish, light green) along with select precursors, including ancestral 
genes (ken/BCL6 and STAT precursor, grey) and precursors along the invertebrate (light 
blue) and vertebrate (pink) lineages. Vertical dotted lines represent the timing of the 
divergence from the common ancestors of invertebrates/vertebrates, bony/cartilaginous 
fish and mammals/birds (red), as well as of WGD events (black). The evolutionary 
trajectory of genes is shown with solid lines, with lineage divergence indicated by red 
dots and duplications by black dots. Abbreviations, WGD: whole genome duplication, 
MYA: million years ago.  
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Table 6.1 Function of BCL6-related proteins 
The extant proteins from invertebrates (fruit-fly, Ken, brown), mammals (human, 
BCL6A, BCL6B, orange) and teleost (zebrafish, Bcl6a, light green) are shown, along 
with known regulators, target genes, functions and role in oncogenesis.
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Protein Regulators Target genes Functions Role in oncogenesis References 
Haematopoietic  Non-haematopoietic 
Ken Upd/Stat93e stat93e, ttk69, ab, scrib hemocytes eye, terminalia, 
testis, neuron 
? (Allen et al. 2007; Arbouzova, Bach & Zeidler 2006; 
Issigonis & Matunis 2012; Wen et al. 2000) 
BCL6A IL-2/STAT5 BCOR, SMRT, ATR, 
CHEK1, TP53, PRDM1, 
PDCD2, CDKN1A, CD69, 
CD44, CD23b, NFKB1, 
NCOR, SIN3A, MTA3, 
HDACs 
GC B cell, T cell, 
DC, macrophage  
growth, myocytes,  
adipocytes, 
spermatocytes  
DLBCL, FL, MCL (Albagli-Curiel et al. 1998; Hollister et al. 2013; 
Huang et al. 2014; Huang, Hatzi & Melnick 2013; 
Kojima et al. 2001; LaPensee et al. 2014; Ranuncolo, 
Polo & Melnick 2008; Toney et al. 2000; Yoshida et 
al. 1999) 
BCL6B PI3K/AKT SMRT, SIN3A, HDACs haematopoietic 
progenitor cells 
(HPC), T cells 
? CLL, CRC, gastric 
cancer, hepatocellular 
carcinoma,  
(Broxmeyer et al. 2007; Gu et al. 2018; Hu et al. 2015; 
Wang et al. 2014) 
Bcl6a Stat5.2 ? B, T, macrophage 
cells 
growth, eye optic cup ? (Lee, Lee & Gross 2013) 
Bcl6b ? ? ? ? ?  
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